<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns="http://purl.org/rss/1.0/"><channel rdf:about="http://www.metabolismjournal.com//inpress?rss=yes"><title>Metabolism - Clinical and Experimental - Articles in Press</title><description>Metabolism - Clinical and Experimental RSS feed: Articles in Press.    
 Metabolism  promotes excellence in research by publishing high-quality original research papers, fast-tracking cutting-edge 
papers, research brief reports, mini-reviews, and other special articles related to all aspects of human metabolism. Work considered 
for publication in  Metabolism  includes studies in humans, animal and cellular models. Work with strong translational potential 
is prioritized.  Metabolism  will consider papers for publication in any aspect of translational and clinical metabolic research, 
including (but not limited to):

 
  Energy Expenditure and Obesity 
   Metabolic Syndrome and Diabetes 
  Nutrition, 
Exercise, and the Environment 
  Genetics, Proteomics, and Metabolomics 
  Carbohydrate, Lipid, and Protein Metabolism

 
  Endocrinology and Hypertension 
  Mineral and Bone Metabolism 
  Cardiovascular Diseases and Malignancies  
 
   </description><link>http://www.metabolismjournal.com//inpress?rss=yes</link><dc:publisher>Elsevier Inc.</dc:publisher><dc:language>en</dc:language><dc:rights> © 2011 Elsevier Inc. All rights reserved. </dc:rights><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:issn>0026-0495</prism:issn><prism:publicationDate>2012-01-18</prism:publicationDate><prism:copyright> © 2011 Elsevier Inc. All rights reserved. </prism:copyright><prism:rightsAgent>healthpermissions@elsevier.com</prism:rightsAgent><items><rdf:Seq><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003945/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003982/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511004203/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003970/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003921/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003933/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003969/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003994/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511004173/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003659/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS002604951100388X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003507/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS002604951100357X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003581/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003635/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003660/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003672/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003684/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003696/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003702/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003878/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003015/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS002604951100343X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003490/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003647/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003532/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003556/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003064/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003155/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003404/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003428/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003441/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003453/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003465/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003489/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003520/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003544/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003568/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003416/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003477/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003519/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003167/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003210/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003027/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003039/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003040/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003052/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003143/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003179/abstract?rss=yes"/><rdf:li rdf:resource="http://www.metabolismjournal.com/article/PIIS0026049511003180/abstract?rss=yes"/></rdf:Seq></items></channel><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003945/abstract?rss=yes"><title>Energy content of weight loss: kinetic features during voluntary caloric restriction - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003945/abstract?rss=yes</link><description>Abstract: The classic rule stating that restricting intake by 3500 kcal/wk will lead to a 1-lb/wk rate of weight loss has come under intense scrutiny. Generally not a component of most weight loss prediction models, the “early” rapid weight loss phase may represent a period during which the energy content of weight change (ΔEC/ΔW) is low and thus does not follow the classic “rule.” The current study tested this hypothesis. Dynamic ΔEC/ΔW changes were examined in 23 Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy Study overweight men and women evaluated by dual-energy x-ray absorptiometry during weight loss at treatment weeks 4 to 24. Changes from baseline in body energy content were estimated from fat and fat-free mass. Repeated-measures analysis of variance was used to determine if ΔEC/ΔW changed significantly over time. The evaluation was expanded with addition of the Kiel 13-week weight loss study of 75 obese men and women to test with adequate power if there are sex differences in ΔEC/ΔW. The analysis of variance CALERIE time effect was significant (P &lt; .001), with post hoc tests indicating that ΔEC/ΔW (kilocalories per kilogram) increased significantly from week 4 (X ± SEM; 4, 858 ± 388) to 6 (6, 041 ± 376, P &lt; .01) and changed insignificantly thereafter; ΔEC/ΔW was significantly larger for Kiel women (6, 804 ± 226) vs men (6, 119 ± 240, P &lt; .05). Sex-specific dynamic relative changes in body composition and related ΔEC/ΔW occur with weight loss initiation that extend for 1 month or more. These observations provide new information for developing energy balance models and further define limitations of the 3500-kcal energy deficit → 1-lb weight loss rule.</description><dc:title>Energy content of weight loss: kinetic features during voluntary caloric restriction - Corrected Proof</dc:title><dc:creator>Steven B. Heymsfield, Diana Thomas, Corby K. Martin, Leanne M. Redman, Boyd Strauss, Anja Bosy-Westphal, Manfred J. Müller, Wei Shen, Allison Martin Nguyen</dc:creator><dc:identifier>10.1016/j.metabol.2011.11.012</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2012)</dc:source><dc:date>2012-01-18</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2012-01-18</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003982/abstract?rss=yes"><title>The effect of gonadal and adrenal steroid therapy on skeletal health in adolescents and young women with anorexia nervosa - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003982/abstract?rss=yes</link><description>Abstract: Anorexia nervosa (AN) is characterized by subnormal estrogen and dehydroepiandrosterone (DHEA) levels. We sought to determine whether the combination of DHEA + estrogen/progestin is superior to placebo in preserving skeletal health over 18 months in AN. Females with AN, aged 13 to 27 years, were recruited for participation in this double-blind, placebo-controlled, randomized trial. Ninety-four subjects were randomized, of whom 80 completed baseline assessments and received either study drug (oral micronized DHEA 50 mg + 20 µg ethinyl estradiol/0.1 mg levonorgestrel combined oral contraceptive pill [COC] daily; n = 43) or placebo (n = 37). Serial measurements of areal bone mineral density (aBMD), bone turnover markers, and serum hormone concentrations were obtained. Sixty subjects completed the 18-month trial. Spinal and whole-body aBMD z scores were preserved in the DHEA + COC group, but decreased in the placebo group (comparing trends, P = .008 and P = .001, respectively). Bone turnover markers initially declined in subjects receiving DHEA + COC and then returned to baseline. No differences in body composition, adverse effects of therapy, or alterations in biochemical safety parameters were observed. Combined therapy with DHEA + COC appears to be safe and effective for preventing bone loss in young women with AN, whereas placebo led to decreases in aBMD. Dehydroepiandrosterone + COC may be safely used to preserve bone mass as efforts to reverse the nutritional, psychological, and other hormonal components of AN are implemented.</description><dc:title>The effect of gonadal and adrenal steroid therapy on skeletal health in adolescents and young women with anorexia nervosa - Corrected Proof</dc:title><dc:creator>Amy D. DiVasta, Henry A. Feldman, Courtney Giancaterino, Clifford J. Rosen, Meryl S. LeBoff, Catherine M. Gordon</dc:creator><dc:identifier>10.1016/j.metabol.2011.11.016</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2012)</dc:source><dc:date>2012-01-18</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2012-01-18</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511004203/abstract?rss=yes"><title>Stress during childhood and adolescence: how to combat? - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511004203/abstract?rss=yes</link><description>I read with much interest the published manuscript entitled “Metabolic consequences of stress during childhood and adolescence” by Pervanidou and Chrousos . The authors have rightly cited facts regarding the potential damage to cardiovascular, nervous, endocrine, and reproductive systems due to the ongoing stress in the critical period of life. I wish to share few scientific facts on this related topic.</description><dc:title>Stress during childhood and adolescence: how to combat? - Corrected Proof</dc:title><dc:creator>Srijit Das</dc:creator><dc:identifier>10.1016/j.metabol.2011.12.011</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2012)</dc:source><dc:date>2012-01-16</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2012-01-16</prism:publicationDate><prism:section>LETTER TO THE EDITOR</prism:section></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003970/abstract?rss=yes"><title>Diabetes, insulin use, and non-Hodgkin lymphoma mortality in Taiwan - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003970/abstract?rss=yes</link><description>Abstract: The objective was to evaluate non-Hodgkin lymphoma (NHL) mortality trends and mortality rate ratios between diabetes patients and the general population, and to study NHL risk factors among diabetes patients in Taiwan. A cohort of 80 397 patients with type 2 diabetes mellitus older than 45 years was recruited in 1995-1998 and followed up until 2006. Age-standardized NHL mortality in 1995-2006 was calculated. Non-Hodgkin lymphoma risk factors in diabetes patients were evaluated using Cox regression. Age-standardized NHL mortality trend was steady. Eighty-two male and 69 female diabetes patients died of NHL (crude mortality rates, 35.1 and 23.0 per 100 000 person-years, respectively; corresponding overall mortality rate ratios comparing diabetes patients to the general population, 2.06 and 2.14). The mortality rate ratios were 1.47, 2.33, and 2.78 for men aged at least 65, 55 to 64, and 45 to 54 years, respectively; the corresponding ratios for women were 1.48, 2.22, and 2.79. Age and male sex were significant risk factors, whereas insulin use, diabetes duration, smoking, body mass index, and area of residence were not. Diabetes duration became a significant factor after excluding patients who died of NHL within 5 years of diabetes diagnosis. Patients with diabetes have a higher risk of mortality from NHL, but insulin use is not associated with NHL mortality. Future studies are needed to fully elucidate any association between increased mortality rate ratio and younger age as well as the lack of association between NHL and insulin use demonstrated herein.</description><dc:title>Diabetes, insulin use, and non-Hodgkin lymphoma mortality in Taiwan - Corrected Proof</dc:title><dc:creator>Chin-Hsiao Tseng</dc:creator><dc:identifier>10.1016/j.metabol.2011.11.015</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2012)</dc:source><dc:date>2012-01-11</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2012-01-11</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003921/abstract?rss=yes"><title>Apolipoprotein E predicts incident cardiovascular disease risk in women but not in men with concurrently high levels of high-density lipoprotein cholesterol and C-reactive protein - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003921/abstract?rss=yes</link><description>Abstract: Although there is great interest in the notion that dysfunctional transformation of high-density lipoprotein (HDL) facilitates development of atherosclerosis and cardiovascular disease (CVD), few studies in human populations directly address this issue. As apolipoprotein E (apoE) is a constituent of HDL thought to be important for HDL antiatherogenic function, we sought to assess the role of apoE in CVD risk in subjects likely to display dysfunctional transformation of HDL. Association of apoE levels with incident CVD risk was investigated using Cox multivariable proportional hazards modeling. Analyses were performed in subgroups of women and men likely to display dysfunctional transformation of HDL deriving from previous subgroup identification based upon defining characteristics of concurrently high levels of HDL cholesterol and systemic inflammation as reflected by high C-reactive protein levels. Results revealed apoE levels (dichotomized as highest quartile vs combined 3 lowest quartiles) as predicting subgroup risk in women (hazard ratio, 4.52; 95% confidence interval, 1.07-19.12; P = .040) but not in men. Further sex differences were manifested in terms of the relationship of apoE levels with age. Analysis revealed positive correlation of apoE levels with age in women (r = 0.47, P &lt; .0001) but not in men (r = 0.04, P = .43). Apolipoprotein E levels predict incident CVD risk in women with high levels of HDL cholesterol and C-reactive protein but not in men. Future studies should be oriented toward investigations of apoE as related to multiplicity of HDL functionality and toward assessment of potential roles for apoE in dysfunctional transformation of HDL.</description><dc:title>Apolipoprotein E predicts incident cardiovascular disease risk in women but not in men with concurrently high levels of high-density lipoprotein cholesterol and C-reactive protein - Corrected Proof</dc:title><dc:creator>James P. Corsetti, Ron T. Gansevoort, Stephan J.L. Bakker, GerJan Navis, Charles E. Sparks, Robin P.F. Dullaart</dc:creator><dc:identifier>10.1016/j.metabol.2011.11.010</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2012)</dc:source><dc:date>2012-01-09</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2012-01-09</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003933/abstract?rss=yes"><title>Effects of PKF275-055, a dipeptidyl peptidase–4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E–null mice - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003933/abstract?rss=yes</link><description>Abstract: We recently discovered that glucagon-like peptide–1 and glucose-dependent insulinotropic polypeptide can both prevent the development of atherosclerosis in apolipoprotein E–null (Apoe−/−) mice. In the present study, we attempted to extend these findings to orally administered dipeptidyl peptidase (DPP)–4 inhibitor. Seventeen-week-old Apoe−/− mice fed an atherogenic diet were administered a DPP-4 inhibitor, vildagliptin analogue (PKF275-055 [PKF], 100 µm/[kg d]), in drinking water over a period of 4 weeks. Aortic atherosclerosis and oxidized low-density lipoprotein–induced foam cell formation were determined. Orally administered PKF increased plasma levels of active glucagon-like peptide–1 by 3.5-fold, increased total glucose-dependent insulinotropic polypeptide levels by 2-fold, reduced body weight by 13%, and reduced plasma cholesterol levels by 30%. Compared with drinking water controls, PKF significantly suppressed total aortic atherosclerotic lesions, atheromatous plaque in the aortic root, and macrophage accumulation in the aortic wall by 30% to 40% (P &lt; .001). None of these changes were associated with the PKF-induced reductions in body weight and plasma cholesterol levels. Foam cell formation was suppressed by 40% in the exudate peritoneal macrophages obtained from the PKF-treated mice. The DPP-4 inhibitor prevents the development of atherosclerotic lesions by suppressing macrophage foam cell formation.</description><dc:title>Effects of PKF275-055, a dipeptidyl peptidase–4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E–null mice - Corrected Proof</dc:title><dc:creator>Michishige Terasaki, Masaharu Nagashima, Takuya Watanabe, Kyoko Nohtomi, Yusaku Mori, Akira Miyazaki, Tsutomu Hirano</dc:creator><dc:identifier>10.1016/j.metabol.2011.11.011</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2012)</dc:source><dc:date>2012-01-09</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2012-01-09</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003969/abstract?rss=yes"><title>Oxysterol sulfation by cytosolic sulfotransferase suppresses liver X receptor/sterol regulatory element binding protein–1c signaling pathway and reduces serum and hepatic lipids in mouse models of nonalcoholic fatty liver disease - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003969/abstract?rss=yes</link><description>Abstract: Cytosolic sulfotransferase (SULT2B1b) catalyzes oxysterol sulfation. 5-Cholesten-3β-25-diol-3-sulfate (25HC3S), one product of this reaction, decreases intracellular lipids in vitro by suppressing liver X receptor/sterol regulatory element binding protein (SREBP)–1c signaling, with regulatory properties opposite to those of its precursor 25-hydroxycholesterol. Upregulation of SULT2B1b may be an effective strategy to treat hyperlipidemia and hepatic steatosis. The objective of the study was to explore the effect and mechanism of oxysterol sulfation by SULT2B1b on lipid metabolism in vivo. C57BL/6 and LDLR−/− mice were fed with high-cholesterol diet or high-fat diet for 10 weeks and infected with adenovirus encoding SULT2B1b. SULT2B1b expressions in different tissues were determined by immunohistochemistry and Western blot. Sulfated oxysterols in liver were analyzed by high-pressure liquid chromatography. Serum and hepatic lipid levels were determined by kit reagents and hematoxylin and eosin staining. Gene expressions were determined by real-time reverse transcriptase polymerase chain reaction and Western Blot. Following infection, SULT2B1b was successfully overexpressed in the liver, aorta, and lung tissues, but not in the heart or kidney. SULT2B1b overexpression, combined with administration of 25-hydroxycholesterol, significantly increased the formation of 25HC3S in liver tissue and significantly decreased serum and hepatic lipid levels, including triglycerides, total cholesterol, free cholesterol, and free fatty acids, as compared with controls in both C57BL/6 and LDLR−/− mice. Gene expression analysis showed that increases in SULT2B1b expression were accompanied by reduction in key regulators and enzymes involved in lipid metabolism, including liver X receptor α, SREBP-1, SREBP-2, acetyl-CoA carboxylase–1, and fatty acid synthase. These findings support the hypothesis that 25HC3S is an important endogenous regulator of lipid biosynthesis.</description><dc:title>Oxysterol sulfation by cytosolic sulfotransferase suppresses liver X receptor/sterol regulatory element binding protein–1c signaling pathway and reduces serum and hepatic lipids in mouse models of nonalcoholic fatty liver disease - Corrected Proof</dc:title><dc:creator>Qianming Bai, Xin Zhang, Leyuan Xu, Genta Kakiyama, Douglas Heuman, Arun Sanyal, William M. Pandak, Lianhua Yin, Wen Xie, Shunlin Ren</dc:creator><dc:identifier>10.1016/j.metabol.2011.11.014</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2012)</dc:source><dc:date>2012-01-09</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2012-01-09</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003994/abstract?rss=yes"><title>The serum concentration of allograft inflammatory factor–1 is correlated with metabolic parameters in healthy subjects - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003994/abstract?rss=yes</link><description>Abstract: Obesity is associated with low-grade chronic inflammation characterized by inflamed adipose tissue with increased infiltration of macrophages. The aim of this study was to investigate the correlations between the serum concentration of allograft inflammatory factor–1 (AIF-1), which is a marker of activated macrophages, and metabolic parameters. The serum AIF-1 concentrations were measured in 303 healthy subjects (163 men and 140 women). We then evaluated the relationships between the serum AIF-1 concentrations and metabolic parameters, including fasting plasma glucose levels, serum lipid concentration, uric acid concentration, and waist circumference. The serum AIF-1 concentrations positively correlated with levels of fasting plasma glucose (r = 0.159, P =.0056), hemoglobin A1c (r = 0.169, P = .0032), triglycerides (r = 0.137, P = .0172), and uric acid (r = 0.146, P = .0108) and with waist circumference (r = 0.221, P = .0001) and body mass index (r = 0.185, P = .0012), whereas the serum AIF-1 concentrations inversely correlated with high-density lipoprotein cholesterol level (r = −0.178, P = .0019). Stepwise multiple regression analysis demonstrated that hemoglobin A1c level (β = .133, F = 5.490, P &lt; .05) and waist circumference (β = .197, F = 11.954, P &lt; .05) were independent predictors of the serum AIF-1 concentrations. The serum AIF-1 concentrations correlated with clinical and biochemical metabolic parameters. Allograft inflammatory factor–1 may be a significant predictor of activated macrophages as well as cardiovascular disease in humans.</description><dc:title>The serum concentration of allograft inflammatory factor–1 is correlated with metabolic parameters in healthy subjects - Corrected Proof</dc:title><dc:creator>Michiaki Fukui, Muhei Tanaka, Hitoshi Toda, Mai Asano, Masahiro Yamazaki, Goji Hasegawa, Saeko Imai, Aya Fujinami, Mitsuhiro Ohta, Naoto Nakamura</dc:creator><dc:identifier>10.1016/j.metabol.2011.12.001</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2012)</dc:source><dc:date>2012-01-09</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2012-01-09</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511004173/abstract?rss=yes"><title>Correction of metabolic abnormalities in a rodent model of obesity, metabolic syndrome, and type 2 diabetes mellitus by inhibitors of hepatic protein kinase C–ι - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511004173/abstract?rss=yes</link><description>Abstract: Excessive activity of hepatic atypical protein kinase (aPKC) is proposed to play a critical role in mediating lipid and carbohydrate abnormalities in obesity, the metabolic syndrome, and type 2 diabetes mellitus. In previous studies of rodent models of obesity and type 2 diabetes mellitus, adenoviral-mediated expression of kinase-inactive aPKC rapidly reversed or markedly improved most if not all metabolic abnormalities. Here, we examined effects of 2 newly developed small-molecule PKC-ι/λ inhibitors. We used the mouse model of heterozygous muscle-specific knockout of PKC-λ, in which partial deficiency of muscle PKC-λ impairs glucose transport in muscle and thereby causes glucose intolerance and hyperinsulinemia, which, via hepatic aPKC activation, leads to abdominal obesity, hepatosteatosis, hypertriglyceridemia, and hypercholesterolemia. One inhibitor, 1H-imidazole-4-carboxamide, 5-amino-1-[2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl-[1R-(1a,2b,3b,4a)], binds to the substrate-binding site of PKC-λ/ι, but not other PKCs. The other inhibitor, aurothiomalate, binds to cysteine residues in the PB1-binding domains of aPKC-λ/ι/ζ and inhibits scaffolding. Treatment with either inhibitor for 7 days inhibited aPKC, but not Akt, in liver and concomitantly improved insulin signaling to Akt and aPKC in muscle and adipocytes. Moreover, both inhibitors diminished excessive expression of hepatic, aPKC-dependent lipogenic, proinflammatory, and gluconeogenic factors; and this was accompanied by reversal or marked improvements in hyperglycemia, hyperinsulinemia, abdominal obesity, hepatosteatosis, hypertriglyceridemia, and hypercholesterolemia. Our findings highlight the pathogenetic importance of insulin signaling to hepatic PKC-ι in obesity, the metabolic syndrome, and type 2 diabetes mellitus and suggest that 1H-imidazole-4-carboxamide, 5-amino-1-[2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl-[1R-(1a,2b,3b,4a)] and aurothiomalate or similar agents that selectively inhibit hepatic aPKC may be useful treatments.</description><dc:title>Correction of metabolic abnormalities in a rodent model of obesity, metabolic syndrome, and type 2 diabetes mellitus by inhibitors of hepatic protein kinase C–ι - Corrected Proof</dc:title><dc:creator>Mini P. Sajan, Sonali Nimal, Stephen Mastorides, Mildred Acevedo-Duncan, C. Ronald Kahn, Alan P. Fields, Ursula Braun, Michael Leitges, Robert V. Farese</dc:creator><dc:identifier>10.1016/j.metabol.2011.12.008</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2012)</dc:source><dc:date>2012-01-09</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2012-01-09</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003659/abstract?rss=yes"><title>Parathyromatosis: a rare yet problematic etiology of recurrent and persistent hyperparathyroidism - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003659/abstract?rss=yes</link><description>Abstract: Recurrent or persistent hyperparathyroidism is an uncommon yet challenging clinical problem, and parathyromatosis is one of its very rare causes. In this minireview, we review causes of recurrent hyperparathyroidism and all cases of parathyromatosis available in the literature. The clinical course of a case of parathyromatosis with the longest follow-up (1977-2011) is described. Similar cases reported between 1975 and the present are reviewed and analyzed to characterize the clinical presentation, course, and management of this rare condition. Parathyromatosis, which is benign parathyroid tissue seeding, has been detailed in 35 patients in the English literature. The majority were female subjects, with end-stage renal disease, in their fifth to sixth decade of life. In most cases, the diagnosis was made intraoperatively; and the condition was often refractory to surgery. A calcimimetic agent was used in 5 cases with end-stage renal disease; serum calcium and/or parathyroid hormone levels decreased in 4 subjects, but only one was reported to experience increments in bone density. Medical management combining a calcimimetic with a bisphosphonate may therefore be a preferred alternative.</description><dc:title>Parathyromatosis: a rare yet problematic etiology of recurrent and persistent hyperparathyroidism - Corrected Proof</dc:title><dc:creator>Mirella P. Hage, Ibrahim Salti, Ghada El-Hajj Fuleihan</dc:creator><dc:identifier>10.1016/j.metabol.2011.11.001</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2012)</dc:source><dc:date>2012-01-05</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2012-01-05</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS002604951100388X/abstract?rss=yes"><title>Characterization of D-3-hydroxybutyrylcarnitine (ketocarnitine): an identified ketosis-induced metabolite - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS002604951100388X/abstract?rss=yes</link><description>Abstract: Hydroxybutyrylcarnitine (HB-carnitine) is a metabolite that has been associated with insulin resistance and type 2 diabetes mellitus. It is currently unknown whether HB-carnitine can be produced from D-3-hydroxybutyrate (D-3HB), a ketone body; but its formation from L-3-HB-CoA, a fatty acid β-oxidation intermediate, is well established. We aimed to assess which stereoisomers of 3-HB-carnitine are present in vivo. Ketosis and increased fatty acid oxidation were induced in 12 lean healthy men by a 38-hour fasting period. The D-3HB kinetics (stable isotope technique) and stereoisomers of muscle 3-HB-carnitine (high-performance liquid chromatography/ultra-performance liquid chromatography–tandem mass spectrometry) were measured. Muscle D-3HB-carnitine content was much higher compared with L-3HB-carnitine. In addition, muscle D-3HB-carnitine correlated significantly with D-3-HB production. Following the finding that a ketone body can be converted into a carnitine ester in vivo, we show in vitro that D-3-HB can be converted into HB-carnitine (ketocarnitine) via an acyl-CoA synthetase reaction in several tissues including human muscle. During fasting, HB-carnitine in muscle is derived mainly from the ketone body D-3HB. The role of D-3HB-carnitine synthesis in metabolism remains to be elucidated.</description><dc:title>Characterization of D-3-hydroxybutyrylcarnitine (ketocarnitine): an identified ketosis-induced metabolite - Corrected Proof</dc:title><dc:creator>Maarten R. Soeters, Mireille J. Serlie, Hans P. Sauerwein, Marinus Duran, Jos P. Ruiter, Willem Kulik, Mariëtte T. Ackermans, Paul E. Minkler, Charles L. Hoppel, Ronald J.A. Wanders, Sander M. Houten</dc:creator><dc:identifier>10.1016/j.metabol.2011.11.009</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2012)</dc:source><dc:date>2012-01-03</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2012-01-03</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003507/abstract?rss=yes"><title>The effect of ziprasidone on body weight and energy expenditure in female rats - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003507/abstract?rss=yes</link><description>Abstract: Ziprasidone, a novel antipsychotic agent with a unique receptor-binding profile, has been reported to have lower propensity for weight gain compared with other atypical antipsychotics. Here, we examined the effects of ziprasidone on resting energy expenditure, physical activity, thermogenesis, food intake, and weight gain in female Sprague-Dawley rats. Ziprasidone (20 mg/kg) or vehicle was administered once daily for 7 weeks; and body weight, food intake, resting energy expenditure, locomotor activity, colonic temperature on cold exposure, and abdominal fat were measured. Compared with control animals, ziprasidone-treated rats gained significantly less weight (P = .031), had a lower level of physical activity (P = .016), showed a higher resting energy expenditure (P &lt; .001), and displayed a greater capacity for thermogenesis when subjected to cold (P &lt; .001). In addition, ziprasidone-treated rats had a lower level of abdominal fat than did controls, although the difference was not significant. Ziprasidone had no effect on food intake. Our results indicate that, in female Sprague-Dawley rats, a 7-week treatment regimen of ziprasidone induces a significant decrease in weight gain by increasing resting energy expenditure without decreasing food intake and even with a lower level of physical activity. Further studies are needed to elucidate the precise mechanism of lower propensity of weight gain of ziprasidone.</description><dc:title>The effect of ziprasidone on body weight and energy expenditure in female rats - Corrected Proof</dc:title><dc:creator>Subin Park, Min-Seon Kim, Churl Namkoong, Min-Hyeon Park, Jin Pyo Hong</dc:creator><dc:identifier>10.1016/j.metabol.2011.10.011</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-30</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-30</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS002604951100357X/abstract?rss=yes"><title>A fruit and dairy dietary pattern is associated with a reduced risk of metabolic syndrome - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS002604951100357X/abstract?rss=yes</link><description>Abstract: This study examines the relationship between adherence to different dietary patterns and the presence of metabolic syndrome and its components among Korean adults. The sample consisted of 406 Korean adults aged 22 to 78 years recruited from hospitals. Metabolic syndrome was defined according to the criteria issued by the Adult Treatment Panel III, with the exception of central obesity, which was defined according to the Asian-Pacific criteria. Dietary information was obtained by means of a 24-hour recall and a 3-day food record, and factor analysis was used to define dietary patterns. Factor analysis identified 4 major dietary patterns, which explained 28.8% of the total variance, based on the percentage of total daily energy intake from each food group: Korean traditional, alcohol and meats, sweets and fast foods, and fruit and dairy. After controlling for all potential confounders, we found that the Korean traditional dietary pattern was not associated with individual components of the metabolic syndrome but was significantly associated with increased odds of having metabolic syndrome. The fruit and dairy pattern was significantly associated with decreased odds of impaired blood glucose, hypertriglyceridemia, and metabolic syndrome. Our findings suggest that the fruit and dairy pattern is associated with reduced risk of having metabolic syndrome.</description><dc:title>A fruit and dairy dietary pattern is associated with a reduced risk of metabolic syndrome - Corrected Proof</dc:title><dc:creator>Soyoung Hong, YoonJu Song, Kye Heui Lee, Hong Soo Lee, Myoungsook Lee, Sun Ha Jee, Hyojee Joung</dc:creator><dc:identifier>10.1016/j.metabol.2011.10.018</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-30</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-30</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003581/abstract?rss=yes"><title>Fatty acid profile of skeletal muscle phospholipid is altered in mdx mice and is predictive of disease markers - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003581/abstract?rss=yes</link><description>Abstract: The mdx mouse is a model for Duchenne muscular dystrophy. The fatty acid (FA) composition in dystrophic muscle could potentially impact the disease severity. We tested FA profiles in skeletal muscle phospholipid (PL) and triglyceride in mdx and control (con) mice to assess associations with disease state as well as correlations with grip strength (which is lower in mdx) and serum creatine kinase (CK, which is elevated in mdx). Compared with con, mdx PL contained less docosahexaenoic acid (P &lt; .001) and more linoleic acid (P = .001). Docosahexaenoic acid contents did not correlate with strength or serum CK. Linoleic acid content in PL was positively correlated with CK in mdx (P &lt; .05) but not con. α-Linolenic acid content in PL was positively correlated with strength in mdx (P &lt; .05) but not con. The FA profile in triglyceride showed less difference between groups and far less predictive ability for disease markers. We conclude that profiling the FA composition of tissue lipids (particularly PL) can be a useful strategy for generating novel biomarkers and potential therapeutic targets in muscle diseases and likely other pathological conditions as well. Specifically, the present results have indicated potential benefits of raising content of particular n-3 FAs (especially α-linolenic acid) and reducing content of particular n-6 FAs (linoleic acid) in PL of dystrophic muscle.</description><dc:title>Fatty acid profile of skeletal muscle phospholipid is altered in mdx mice and is predictive of disease markers - Corrected Proof</dc:title><dc:creator>Marc A. Tuazon, Gregory C. Henderson</dc:creator><dc:identifier>10.1016/j.metabol.2011.10.019</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-30</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-30</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003635/abstract?rss=yes"><title>The ACE insertion/deletion polymorphism and its association with metabolic syndrome - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003635/abstract?rss=yes</link><description>Abstract: The angiotensin-1–converting enzyme (ACE) gene has been suggested to be involved in the development of metabolic syndrome (MetS). However, results have been inconsistent. In this study, a meta-analysis was performed to investigate the association between ACE insertion/deletion (I/D) polymorphism and MetS. Published literature from PubMed, EMBASE, and ISI Web of Science databases was searched for eligible publications. All studies assessing the association between ACE I/D polymorphism and MetS were included. Pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were calculated using a fixed- or random-effects model. Ten studies (1939 cases/2845 controls) for ACE I/D polymorphism were included in this meta-analysis. Most of the studies were performed in whites. The ACE I/D polymorphism was associated with an increased OR of MetS under a dominant model (DD + ID vs II: OR = 1.39; 95% CI, 1.22-1.60; P &lt; .001). Using this model, similar results were found among studies using different ethnic populations, studies using different MetS definitions, and studies with more than 100 cases. This meta-analysis indicated that the D allele of the ACE gene, known to be related to higher levels of angiotensinogen, is associated with an increased OR of MetS. However, given the limited sample size, this association warrants further investigation.</description><dc:title>The ACE insertion/deletion polymorphism and its association with metabolic syndrome - Corrected Proof</dc:title><dc:creator>Bo Xi, Rikje Ruiter, Jie Chen, Haiyan Pan, Ying Wang, Jie Mi</dc:creator><dc:identifier>10.1016/j.metabol.2011.10.022</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-30</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-30</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003660/abstract?rss=yes"><title>Is perilipin critical in fat utilization during exercise? - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003660/abstract?rss=yes</link><description>How could it be possible for somebody to compete in an Ironman competition and a 100-km ultramarathon without hypoglycemia? The answer would be our body's ability to mobilize and use stored fat. Endogenous triacylglycerol (TG) represents the largest fuel reservoir in the body, mostly stored in the adipose tissue, but also some in skeletal muscle and plasma. Because the energy source from TG in the body is approximately 60 times higher than that of glycogen, an intact TG metabolism is important during prolonged fasting or long-term exercise . During the course of short-term fasting and exercise, a limited amount of lipids present in most tissues is hydrolyzed and used. However, stored TG must be mobilized by the induction of lipolysis in adipocytes if fasting or exercise lasts longer. Therefore, complex machinery of lipolysis of adipose tissue and their interaction with skeletal muscle need to be in place for normal endurance-exercise performance.</description><dc:title>Is perilipin critical in fat utilization during exercise? - Corrected Proof</dc:title><dc:creator>Justin Y. Jeon, Young-Bum Kim</dc:creator><dc:identifier>10.1016/j.metabol.2011.11.002</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-30</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-30</prism:publicationDate><prism:section>EDITORIAL</prism:section></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003672/abstract?rss=yes"><title>Early nutritional changes induce sexually dimorphic long-term effects on body weight gain and the response to sucrose intake in adult rats - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003672/abstract?rss=yes</link><description>Abstract: Long-term metabolic effects induced by early nutritional changes are suspected to differ between males and females, but few studies have analyzed both sexes simultaneously. We analyzed the consequences of neonatal nutritional changes on body weight (BW) and the adult response to a sucrose-enriched diet in both male and female rats. Litter size was manipulated at birth to induce over- and undernutrition (4 pups: L4; 12 pups: L12; 20 pups: L20). From 50 to 65 days of age, half of each group received a 33% sucrose solution instead of water. Serum leptin, insulin, and ghrelin levels were analyzed at day 65. At weaning, rats from L4 weighed more and those from L20 weighed less than controls (L12). Body weight was greater in L4 rats throughout the study and increased further compared with controls in adult life. L20 males ate less and gained less weight throughout the study, but L20 females had a significant catch-up in BW. Sucrose intake increased total energy consumption in all groups, but not BW gain, with L4 males and L4 and L20 females reducing weight gain. Yet, sucrose intake increased serum leptin levels, with this increase being significant in L4 and L20 males. Our results suggest that females are more capable than males of recuperating and maintaining a normal BW after reduced neonatal nutrition. Furthermore, increased sucrose intake does not increase BW, but could alter body composition as reflected by leptin levels, with the percentage of calories consumed in the form of sucrose being affected by sex and neonatal nutrition.</description><dc:title>Early nutritional changes induce sexually dimorphic long-term effects on body weight gain and the response to sucrose intake in adult rats - Corrected Proof</dc:title><dc:creator>Esther Fuente-Martín, Miriam Granado, Cristina García-Cáceres, Miguel A. Sanchez-Garrido, Laura M. Frago, Manuel Tena-Sempere, Jesús Argente, Julie A. Chowen</dc:creator><dc:identifier>10.1016/j.metabol.2011.11.003</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-30</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-30</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003684/abstract?rss=yes"><title>The reliability of using the single-biopsy approach to assess basal muscle protein synthesis rates in vivo in humans - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003684/abstract?rss=yes</link><description>Abstract: It has recently been proposed that basal muscle protein synthesis can be effectively assessed by measuring the background enrichment in total plasma protein, thereby omitting the initial biopsy, and determining the difference in enrichment from a single muscle biopsy obtained during a primed continuous infusion of isotope-labeled amino acids. We determined the reliability of calculating basal mixed muscle protein fractional synthetic rates (FSRs) from mixed plasma proteins and a single muscle biopsy compared against the sequential muscle biopsy approach. Ten men (age, 23 ± 1 years; body mass index, 22 ± 1 kg∙m−2) received muscle biopsies of the vastus lateralis after 2 and 4 hours of a primed continuous infusion of l-[ring-13C6]phenylalanine. Mixed muscle protein FSR was calculated from baseline plasma enrichments and muscle protein enrichments determined from the biopsy at 2 hours (1BX SHORT) or 4 hours (1BX LONG), or between muscle protein enrichments at 2 and 4 hours (2BX) of the infusion. No differences (P = .50) were observed in mixed muscle protein FSR, using plasma [ring-13C6]phenylalanine enrichments as the precursor, between the 1BX SHORT (0.031% ± 0.010%∙h−1), 1BX LONG (0.032% ± 0.007%∙h−1), or 2BX (0.035% ± 0.011%∙h−1) approach. A significant correlation was observed between the calculated muscle protein FSR assessed using the 1BX LONG and 2BX approach (r = 0.7, P = .02). Our data demonstrate that the single-biopsy approach, irrespective of whether the biopsy is obtained at 2 or 4 hours, can be used as a surrogate for the sequential-biopsy approach to determine basal muscle protein synthesis in a group.</description><dc:title>The reliability of using the single-biopsy approach to assess basal muscle protein synthesis rates in vivo in humans - Corrected Proof</dc:title><dc:creator>Nicholas A. Burd, Bart B.L. Groen, Milou Beelen, Joan M.G. Senden, Annemie P. Gijsen, Luc J.C. van Loon</dc:creator><dc:identifier>10.1016/j.metabol.2011.11.004</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-30</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-30</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003696/abstract?rss=yes"><title>Resveratrol improves insulin resistance of catch-up growth by increasing mitochondrial complexes and antioxidant function in skeletal muscle - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003696/abstract?rss=yes</link><description>Abstract: Caloric restriction followed by refeeding, a phenomenon known as catch-up growth (CUG), affects mitochondrial function and results in systemic insulin resistance (IR). We investigated the potential of resveratrol (RES) in CUG to prevent IR by increasing activity of the mitochondrial respiratory chain and antioxidant enzymes in skeletal muscle. Rats (8 weeks of age) were divided into 3 groups: normal chow, CUG, and CUG with RES intervention. Skeletal muscle and systemic IR were measured in each group after 4 and 8 weeks. Mitochondrial biogenesis and function, oxidative stress levels, and antioxidant enzyme activity in skeletal muscle were assessed. Catch-up growth–induced IR resulted in significant reductions in both average glucose infusion rate60-120 at euglycemia and skeletal muscle glucose uptake. Mitochondrial citrate synthase activity was lower; and the activity of complexes I to IV in the intermyofibrillar and subsarcolemmal (SS) mitochondria were reduced by 20% to 40%, with the decrease being more pronounced in the SS fraction. Reactive oxygen species levels were significantly higher in intermyofibrillar and SS mitochondria, whereas activities of antioxidant enzymes were decreased. Oral administration of RES, however, increased silent information regulator 1 activity and improved mitochondrial number and insulin sensitivity. Resveratrol treatment decreased levels of reactive oxygen species and restored activities of antioxidant enzymes. This study demonstrates that RES protects insulin sensitivity of skeletal muscle by improving activities of mitochondrial complexes and antioxidant defense status in CUG rats. Thus, RES has therapeutic potential for preventing CUG-related metabolic disorders.</description><dc:title>Resveratrol improves insulin resistance of catch-up growth by increasing mitochondrial complexes and antioxidant function in skeletal muscle - Corrected Proof</dc:title><dc:creator>Juan Zheng, Lu-Lu Chen, Hao-Hao Zhang, Xiang Hu, Wen Kong, Di Hu</dc:creator><dc:identifier>10.1016/j.metabol.2011.11.005</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-30</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-30</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003702/abstract?rss=yes"><title>Diurnal salivary cortisol and urinary catecholamines are associated with diabetes mellitus: the Multi-Ethnic Study of Atherosclerosis - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003702/abstract?rss=yes</link><description>Abstract: The objective was to examine the cross-sectional association of diurnal salivary cortisol curve components and urinary catecholamines with diabetes status. Up to 18 salivary cortisol samples over 3 days and overnight urinary catecholamines were collected from 1002 participants in the Multi-Ethnic Study of Atherosclerosis. Diabetes was defined as a fasting blood glucose of at least 126 mg/dL or medication use. Cortisol curve measures included awakening cortisol, cortisol awakening response, early decline, late decline, and cortisol area under the curve (AUC). Urinary catecholamines included epinephrine, norepinephrine, and dopamine. Participants with diabetes had significantly lower cortisol awakening response (β = −0.19; 95% confidence interval [CI], −0.34 to −0.04) than those without diabetes in multivariable models. Whereas men with diabetes had a nonsignificant trend toward lower total AUC (β = −1.56; 95% CI, −3.93 to 0.80), women with diabetes had significantly higher total AUC (β = 2.62; 95% CI, 0.72 to 4.51) (P = .02 for interaction) compared with those without diabetes. Men but not women with diabetes had significantly lower urinary catecholamines compared with those without diabetes (P &lt; .05). Diabetes is associated with neuroendocrine dysregulation, which may differ by sex. Further studies are needed to determine the role of the neuroendocrine system in the pathophysiology of diabetes.</description><dc:title>Diurnal salivary cortisol and urinary catecholamines are associated with diabetes mellitus: the Multi-Ethnic Study of Atherosclerosis - Corrected Proof</dc:title><dc:creator>Shivam Champaneri, Xiaoqiang Xu, Mercedes R. Carnethon, Alain G. Bertoni, Teresa Seeman, Ana Diez Roux, Sherita Hill Golden</dc:creator><dc:identifier>10.1016/j.metabol.2011.11.006</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-30</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-30</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003878/abstract?rss=yes"><title>Antisense reduction of 11β-hydroxysteroid dehydrogenase type 1 enhances energy expenditure and insulin sensitivity independent of food intake in C57BL/6J mice on a Western-type diet - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003878/abstract?rss=yes</link><description>Abstract: We recently reported that inhibition of 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) by antisense oligonucleotide (ASO) improved hepatic lipid metabolism independent of food intake. In that study, 11β-HSD1 ASO-treated mice lost weight compared with food-matched control ASO-treated mice, suggesting treatment-mediated increased energy expenditure. We have now examined the effects of 11β-HSD1 ASO treatment on adipose tissue metabolism, insulin sensitivity, and whole-body energy expenditure. We used an ASO to knock down 11β-HSD1 in C57BL/6J mice consuming a Western-type diet (WTD). The 11β-HSD1 ASO-treated mice consumed less food, so food-matched control ASO-treated mice were also evaluated. We characterized body composition, gene expression of individual adipose depots, and measures of energy metabolism. We also investigated glucose/insulin tolerance as well as acute insulin signaling in several tissues. Knockdown of 11β-HSD1 protected against WTD-induced obesity by reducing epididymal, mesenteric, and subcutaneous white adipose tissue while activating thermogenesis in brown adipose tissue. The latter was confirmed by demonstrating increased energy expenditure in 11β-HSD1 ASO-treated mice. The 11β-HSD1 ASO treatment also protected against WTD-induced glucose intolerance and insulin resistance; this protection was associated with smaller cells and fewer macrophages in epididymal white adipose tissue as well as enhanced in vivo insulin signaling. Our results indicate that ASO-mediated inhibition of 11β-HSD1 can protect against several WTD-induced metabolic abnormalities. These effects are, at least in part, mediated by increases in the oxidative capacity of brown adipose tissue.</description><dc:title>Antisense reduction of 11β-hydroxysteroid dehydrogenase type 1 enhances energy expenditure and insulin sensitivity independent of food intake in C57BL/6J mice on a Western-type diet - Corrected Proof</dc:title><dc:creator>Guoping Li, Antonio Hernandez-Ono, Rosanne M. Crooke, Mark J. Graham, Henry N. Ginsberg</dc:creator><dc:identifier>10.1016/j.metabol.2011.11.008</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-30</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-30</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003015/abstract?rss=yes"><title>Dual pathways of p53 mediated glucolipotoxicity-induced apoptosis of rat cardiomyoblast cell: activation of p53 proapoptosis and inhibition of Nrf2-NQO1 antiapoptosis - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003015/abstract?rss=yes</link><description>Abstract: Reactive oxygen species (ROS), driven by excessive levels of glucose and free fatty acids, appears to induce cell apoptosis. However, the underlying molecular mechanism of this process remains unclear in cardiac myocytes. We investigated the glucolipotoxicity effects of high glucose and palmitic acid (C16:0) on the rat cardiomyoblast cell line (H9c2) focusing on tumor suppressor p53. Cultured H9c2 rat cardiomyoblasts were exposed to palmitate and /or to an elevated glucose concentration for 18 hours. Only the glucolipotoxic condition of 30 mM glucose in combination with 250μM palmitate resulted in significant generation of ROS and upregulation of p53 which caused to an increased cleavage of caspase-3. On the other hand, the expression of NF-E2-related factor 2 (Nrf2) showed increased tendency while the expression of NAD(P)H: quinone oxidoreductase-1 (NQO1) was decreased. N-acetyl L cysteins and pifithrin-α, an inhibitor of p53 abrogated glucolipotoxicity-induced ROS generation and p53 expression. Chromatin immunoprecipitation analysis revealed that p53 interacted antioxidant responsive elements (ARE)-containing promoter of NQO1. Upregulated p53 counteracted the Nrf2-induced transcription of ARE-containing promoter of NQO1 gene and leaded to decrease in NQO1 expression. We demonstrated that the elevated p53 mediated glucolipotoxicity-induced apoptosis of rat cardiomyoblast cell through dual pathways: stimulating pro-apoptosis signaling as well as suppressing anti-apoptosis pathway of Nrf2-NQO1 signaling.</description><dc:title>Dual pathways of p53 mediated glucolipotoxicity-induced apoptosis of rat cardiomyoblast cell: activation of p53 proapoptosis and inhibition of Nrf2-NQO1 antiapoptosis - Corrected Proof</dc:title><dc:creator>Hye Jin Wang, Eun Young Lee, Seung Jin Han, Soo Hyun Kim, Byung-Wan Lee, Chul Woo Ahn, Bong Soo Cha, Hyun Chul Lee</dc:creator><dc:identifier>10.1016/j.metabol.2011.09.005</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-09</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-09</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS002604951100343X/abstract?rss=yes"><title>Visceral fat accumulation is an indicator of adipose tissue macrophage infiltration in women - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS002604951100343X/abstract?rss=yes</link><description>Abstract: We tested the hypothesis that visceral obesity is the best correlate of abdominal adipose tissue macrophage infiltration in women. Omental and subcutaneous fat samples were surgically obtained from 40 women (age, 47.0 ± 4.0 years; body mass index, 28.4 ± 5.8 kg/m2). CD68+ cells were identified using fluorescence immunohistochemistry. Expression of macrophage markers was measured by real-time reverse transcriptase polymerase chain reaction. Body composition and fat distribution were measured by dual-energy x-ray absorptiometry and computed tomography, respectively. Mean CD68+ cell percentage tended to be higher in subcutaneous (18.3%) compared with omental adipose tissue (15.5%, P = .07). Positive correlations were observed between CD68+ cell percentage as well as CD68 messenger RNA expression in a given depot vs the other (P ≤ .01). Visceral adipose tissue area and omental adipocyte diameter were positively related to CD68+ cell percentage in omental fat (r = 0.52 and r = 0.35, P ≤ .05). Total and visceral adipose tissue areas as well as subcutaneous adipocyte diameter were significantly correlated with CD68+ cell percentage in subcutaneous adipose tissue (0.32 ≤ r ≤ 0.40, P ≤ .05). Adipose tissue areas and subcutaneous adipocyte diameter were also significantly associated with expression of commonly used macrophage markers including CD68 in the subcutaneous fat compartment (0.32 ≤ r ≤ 0.57, P ≤ .05). Visceral adipose tissue area was the best correlate of CD68+ cell percentage in both omental and subcutaneous fat tissues, explaining, respectively, 20% and 12% of the variance in models also including subcutaneous adipose tissue area, adipocyte sizes, and total body fat mass. Visceral adipose tissue accumulation is the best correlate of macrophage infiltration in both the subcutaneous and omental fat compartments of lean to obese women.</description><dc:title>Visceral fat accumulation is an indicator of adipose tissue macrophage infiltration in women - Corrected Proof</dc:title><dc:creator>Andréanne Michaud, Renée Drolet, Suzanne Noël, Gaëtan Paris, André Tchernof</dc:creator><dc:identifier>10.1016/j.metabol.2011.10.004</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-09</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-09</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003490/abstract?rss=yes"><title>Insulin resistance occurs in parallel with sensory neuropathy in streptozotocin-induced diabetes in rats: differential response to early vs late insulin supplementation - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003490/abstract?rss=yes</link><description>Abstract: We investigated whether progressive sensory neuropathy was accompanied by changes in whole-body insulin sensitivity (WBIS) in rats made diabetic by streptozotocin (STZ). The effects of early and late insulin supplementation were also studied. The STZ-treated rats failed to gain weight and exhibited stable hyperglycemia and low plasma insulin levels with a decrease in nerve conduction velocity (NCV) measured in A and C fibers of the saphenous nerve. A decreased sensory neuropeptide (SNP) release such as that of substance P, somatostatin, and calcitonin gene–related peptide determined from organ fluid of tracheal preparations subjected to electrical field stimulation also occurred in diabetic animals. These features were accompanied by a decrease in WBIS measured by hyperinsulinemic-euglycemic glucose clamping and a decrease in insulin-stimulated glucose uptake in cardiac and gastrocnemius muscle. When insulin supplementation with slow-release implants (2 IU/d) was started 4 weeks after STZ injection, blood glucose level normalized. Both insulin sensitivity and sensory nerve function reflected in either NCV or SNP release completely recovered by the 12th post-STZ week. When the insulin implants were applied from the eighth post-STZ week, both WBIS and glucose uptake remained significantly decreased, with a seriously impaired NCV and SNP release with strong hyperglycemia. Late insulin supplementation, however, even by using double implantation from the 10th post-STZ week, was unable to restore blood glucose, WBIS, NCV, and SNP release by the 12th week. Insulin resistance occurs in parallel with sensory neuropathy in STZ-diabetic rats. Both can be improved by early but not late insulin supplementation.</description><dc:title>Insulin resistance occurs in parallel with sensory neuropathy in streptozotocin-induced diabetes in rats: differential response to early vs late insulin supplementation - Corrected Proof</dc:title><dc:creator>Zoltán Szilvássy, Joseph Németh, Péter Kovács, György Paragh, Réka Sári, László Vígh, Barna Peitl</dc:creator><dc:identifier>10.1016/j.metabol.2011.10.010</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-09</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-09</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003647/abstract?rss=yes"><title>Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet–fed KK-Ay mice - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003647/abstract?rss=yes</link><description>Abstract: Type 2 diabetes mellitus is frequently accompanied by fatty liver/nonalcoholic fatty liver disease. Hence, accumulation of lipids in the liver is considered to be one of the risk factors for insulin resistance and metabolic syndrome. Ursodeoxycholic acid (UDCA) is widely used for the treatment of liver dysfunction. We investigated the therapeutic effects of UDCA on type 2 diabetes mellitus exacerbating hepatic steatosis and the underlying mechanisms of its action using KK-Ay mice fed a high-fat diet. KK-Ay mice were prefed a high-fat diet; and 50, 150, and 450 mg/kg of UDCA was orally administered for 2 or 3 weeks. Administration of UDCA decreased fasting hyperglycemia and hyperinsulinemia. Hyperinsulinemic-euglycemic clamp analyses showed that UDCA improved hepatic (but not peripheral) insulin resistance. Hepatic triglyceride and cholesterol contents were significantly reduced by treatment with UDCA, although the genes involved in the synthesis of fatty acids and cholesterol, including fatty acid synthase and 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, were upregulated. Fecal levels of bile acids, neutral sterols, fatty acids, and phospholipids were significantly increased by UDCA treatment. The gene expression levels and protein phosphorylation levels of endoplasmic reticulum stress markers were not changed by UDCA treatment. These results indicate that UDCA ameliorates hyperglycemia and hyperinsulinemia by improving hepatic insulin resistance and steatosis in high-fat diet–fed KK-Ay mice. Reduction of hepatic lipids might be due to their excretion in feces, followed by enhanced utilization of glucose for the synthesis of fatty acids and cholesterol. Ursodeoxycholic acid should be effective for the treatment of type 2 diabetes mellitus accompanying hepatic steatosis.</description><dc:title>Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet–fed KK-Ay mice - Corrected Proof</dc:title><dc:creator>Takuma Tsuchida, Muneshige Shiraishi, Tetsuya Ohta, Kaoru Sakai, Shinichi Ishii</dc:creator><dc:identifier>10.1016/j.metabol.2011.10.023</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-09</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-09</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003532/abstract?rss=yes"><title>Administration of hydrogen-saturated saline decreases plasma low-density lipoprotein cholesterol levels and improves high-density lipoprotein function in high-fat diet–fed hamsters - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003532/abstract?rss=yes</link><description>Abstract: Hydrogen (dihydrogen; H2) has an antiatherosclerotic effect in apolipoprotein (apo) E knockout mice. The goals of this study were to further characterize the effects of H2 on the content, composition, and biological activities of plasma lipoproteins in golden hamsters. Plasma analysis by enzymatic method and fast protein liquid chromatography showed that 4-week intraperitoneal injection of hydrogen-saturated saline remarkably decreased plasma total cholesterol and low-density lipoprotein (LDL) cholesterol levels in high-fat diet–fed hamsters. Sodium dodecyl sulfate polyacrylamide gel electrophoresis analysis of apolipoproteins from ultracentrifugally isolated plasma lipoproteins revealed a marked decrease of apo B100 and apo B48 in LDL. A profound decrease of apo E level in very low-density lipoprotein was also observed. Besides, we determined the functional quality of high-density lipoprotein (HDL) particles isolated from H2-treated and control mice. H2 significantly improved HDL functionality assessed in 2 independent ways, namely, (1) stimulation of cholesterol efflux from macrophage foam cells by measuring HDL-induced [3H]cholesterol efflux and (2) protection against LDL oxidation as a measure of Cu2+-induced thiobarbituric acid reactive substances formation. Administration of hydrogen-saturated saline decreases plasma LDL cholesterol and apo B levels and improves hyperlipidemia-injured HDL functions, including the capacity of enhancing cellular cholesterol efflux and playing antioxidative properties, in high-fat diet–fed hamsters.</description><dc:title>Administration of hydrogen-saturated saline decreases plasma low-density lipoprotein cholesterol levels and improves high-density lipoprotein function in high-fat diet–fed hamsters - Corrected Proof</dc:title><dc:creator>Chuanlong Zong, Guohua Song, Shutong Yao, Luqin Li, Yang Yu, Lei Feng, Shoudong Guo, Tian Luo, Shucun Qin</dc:creator><dc:identifier>10.1016/j.metabol.2011.10.014</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-08</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-08</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003556/abstract?rss=yes"><title>Physical activity is independently associated with multiple measures of arterial stiffness in adolescents and young adults - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003556/abstract?rss=yes</link><description>Abstract: Physical activity (PA) is associated with decreased levels of arterial stiffness in adults, but the relationship between PA and multiple measures of arterial stiffness in adolescents and young adults is not clear. The objective of this study was to test the hypothesis that PA is an independent predictor of multiple measures of arterial stiffness in adolescents and young adults. A total of 548 participants were enrolled in a study of the cardiovascular effects of obesity and type 2 diabetes mellitus (T2DM) (lean, 201; obese, 191; T2DM, 156). Anthropometrics, blood pressure, central and peripheral measures of arterial stiffness (pulse wave velocity, brachial distensibility, and augmentation index), blood (lipids and metabolic tests), and accelerometry data were collected. General linear modeling was performed to test for the independent relationship of PA on arterial stiffness. The mean age of the participants was 17.9 years (standard deviation, 3.5 years). After adjusting for other cardiovascular disease risk factors such as age, sex, body size, mean arterial pressure, and the presence of obesity or T2DM, PA was an independent predictor of augmentation index and brachial distensibility (P &lt; .001). A greater effect of PA on pulse wave velocity was found in participants with T2DM (P = .009) compared with participants in the lean or obese groups. Physical activity is significantly and independently associated with multiple measures of arterial stiffness in adolescents and young adults. The role of PA in the prevention of cardiovascular disease target organ damage in youth, independent of energy balance, merits further exploration.</description><dc:title>Physical activity is independently associated with multiple measures of arterial stiffness in adolescents and young adults - Corrected Proof</dc:title><dc:creator>Nicholas M. Edwards, Stephen R. Daniels, Randall P. Claytor, Philip R. Khoury, Lawrence M. Dolan, Thomas R. Kimball, Elaine M. Urbina</dc:creator><dc:identifier>10.1016/j.metabol.2011.10.016</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-08</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-08</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003064/abstract?rss=yes"><title>Leisure time and occupational physical activity in relation to obesity and insulin resistance: a population-based study from the Skaraborg Project in Sweden - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003064/abstract?rss=yes</link><description>Abstract: The objective was to study obesity and insulin resistance in relation to leisure time physical activity (LTPA) and occupational physical activity (OPA) in a Swedish population, with particular focus on sex differences. Using a cross-sectional design, waist circumference, body mass index (BMI), glucose/insulin metabolism, blood pressure, heart rate, self-reported education, smoking, alcohol consumption, LTPA, and OPA were assessed in 1745 men and women (30-74 years) randomly chosen from 2 municipalities in southwestern Sweden. In both men and women, LTPA was inversely associated with BMI, waist circumference, and the homeostasis model assessment of insulin resistance (HOMA-IR), respectively. These associations remained statistically significant after adjustments for age, OPA, education, alcohol consumption, smoking, and study area, and also for BMI in the analyses concerning waist circumference and HOMA-IR. A statistically significant interaction term (P = .030), adjusted for multiple confounders, revealed a stronger association between LTPA and HOMA-IR in women compared with men. Occupational physical activity was positively associated with BMI (P &lt; .001), waist circumference (P &lt; .001), and HOMA-IR (P = .001), however, only in women. These associations remained when adjusting for multiple confounders. The sex differences were confirmed by statistically significant interaction terms between sex and OPA in association with BMI, waist circumference, and HOMA-IR, respectively. The observed sex differences regarding the strength of the association between LTPA and insulin resistance, and the positive association between OPA and obesity and insulin resistance found solely in women, warrant further investigation. Although exploration of the metabolic effects of OPA appears to be needed, thorough measurement of potential confounders is also vital to understand contextual effects.</description><dc:title>Leisure time and occupational physical activity in relation to obesity and insulin resistance: a population-based study from the Skaraborg Project in Sweden - Corrected Proof</dc:title><dc:creator>Charlotte A. Larsson, Lotte Krøll, Louise Bennet, Bo Gullberg, Lennart Råstam, Ulf Lindblad</dc:creator><dc:identifier>10.1016/j.metabol.2011.09.010</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-07</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-07</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003155/abstract?rss=yes"><title>Effects of high-fructose corn syrup and sucrose on the pharmacokinetics of fructose and acute metabolic and hemodynamic responses in healthy subjects - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003155/abstract?rss=yes</link><description>Abstract: It is unclear whether high-fructose corn syrup (HFCS), which contains a higher amount of fructose and provides an immediate source of free fructose, induces greater systemic concentrations of fructose as compared with sucrose. It is also unclear whether exposure to higher levels of fructose leads to increased fructose-induced adverse effects. The objective was to prospectively compare the effects of HFCS- vs sucrose-sweetened soft drinks on acute metabolic and hemodynamic effects. Forty men and women consumed 24 oz of HFCS- or sucrose-sweetened beverages in a randomized crossover design study. Blood and urine samples were collected over 6 hours. Blood pressure, heart rate, fructose, and a variety of other metabolic biomarkers were measured. Fructose area under the curve and maximum concentration, dose-normalized glucose area under the curve and maximum concentration, relative bioavailability of glucose, changes in postprandial concentrations of serum uric acid, and systolic blood pressure maximum levels were higher when HFCS-sweetened beverages were consumed as compared with sucrose-sweetened beverages. Compared with sucrose, HFCS leads to greater fructose systemic exposure and significantly different acute metabolic effects.</description><dc:title>Effects of high-fructose corn syrup and sucrose on the pharmacokinetics of fructose and acute metabolic and hemodynamic responses in healthy subjects - Corrected Proof</dc:title><dc:creator>MyPhuong T. Le, Reginald F. Frye, Christopher J. Rivard, Jing Cheng, Kim K. McFann, Mark S. Segal, Richard J. Johnson, Julie A. Johnson</dc:creator><dc:identifier>10.1016/j.metabol.2011.09.013</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-07</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-07</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003404/abstract?rss=yes"><title>Change of energy expenditure from physical activity is the most powerful determinant of improved insulin sensitivity in overweight patients with coronary artery disease participating in an intensive lifestyle modification program - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003404/abstract?rss=yes</link><description>Abstract: The objective was to evaluate the determinants of change (Δ) in insulin sensitivity in overweight coronary artery disease male patients without diabetes after an intensive lifestyle intervention. All patients received nutritional counseling and performed 4 months of exercise training (ET) according to 1 of 2 protocols: aerobic ET (65%-70% of peak aerobic capacity [VO2]) 25 to 40 minutes 3 times a week (n = 30) or walking (50%-60% of peak VO2) 45 to 60 minutes at least 5 times a week (n = 30). Data from participants of both ET groups were pooled, and post–intensive lifestyle intervention results were compared with baseline data. The primary outcome was Δ insulin sensitivity (m-value) assessed by the criterion standard technique, the euglycemic-hyperinsulinemic clamp. Changes in weight, body mass index, total and percentage fat mass (by dual-energy x-ray absorptiometry scan), waist circumference, total abdominal and visceral fat (by computed tomographic scan), high-sensitivity C-reactive protein, peak VO2, daily energy intake, and physical activity energy expenditure (PAEE) (by doubly labeled water technique) were also assessed. Daily energy intake decreased by 335 kcal, and PAEE increased by 482 kcal/d (all P &lt; .0001). The mean weight loss was 6.4 kg, and the mean improvement in m-value was 1.6 mg/kg fat-free mass per minute. Univariate determinants of Δ m-value were low baseline PAEE, walking protocol, Δ weight, Δ body mass index, Δ total and percentage fat mass, Δ waist circumference, Δ total abdominal and visceral fat, and Δ PAEE (all P &lt; .05). In multivariate analysis, the only significant determinant of Δ m-value was Δ PAEE (P &lt; .02). In this analysis, the most powerful determinant of improved insulin sensitivity in overweight coronary artery disease patients is the change in PAEE.</description><dc:title>Change of energy expenditure from physical activity is the most powerful determinant of improved insulin sensitivity in overweight patients with coronary artery disease participating in an intensive lifestyle modification program - Corrected Proof</dc:title><dc:creator>Marie C. Audelin, Patrick D. Savage, Michael J. Toth, Jean Harvey-Berino, David J. Schneider, Janice Y. Bunn, Maryann Ludlow, Philip A. Ades</dc:creator><dc:identifier>10.1016/j.metabol.2011.10.001</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-07</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-07</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003428/abstract?rss=yes"><title>In vivo nitric oxide synthesis, insulin sensitivity, and asymmetric dimethylarginine in obese subjects without and with metabolic syndrome - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003428/abstract?rss=yes</link><description>Abstract: Metabolic syndrome (MetSyn) is associated with impaired endothelial function. Here the association between nitric oxide (NO) production and insulin sensitivity (Si) in obese subjects with and without MetSyn was evaluated. The relationship between NO production and asymmetric dimethylarginine (ADMA) was also explored. Seven healthy normal-weight subjects (male/female [M/F], 3/4; age, 27.4 ± 10.9 years; body mass index [BMI], 21.9 ± 2.2 kg/m2), 7 obese subjects without MetSyn (M/F, 1/6; age, 48.0 ± 8.0 years; BMI, 34.5 ± 2.3 kg/m2), and 7 with MetSyn (M/F, 3/4; age, 48.0 ± 10.7 years; BMI, 33.4 ± 2.9 kg/m2) were recruited. Body composition and cardiometabolic functions (blood pressure, glucose, insulin, triglycerides, total cholesterol, high-density lipoprotein, ADMA) were measured. A frequent sampling intravenous glucose tolerance test was performed to measure Si. A novel stable isotopic method was used to measure in vivo rates of NO production. The NO production was lower in obese subjects with MetSyn compared with normal-weight subjects and obese subjects without MetSyn. Similarly, Si was significantly lower in obesity, both without and with MetSyn, compared with the control group. A significant direct association was found between NO synthesis and Si (ρ = 0.47, P = .03). Circulating levels of ADMA were significantly higher in the obese group with MetSyn. A nonsignificant negative trend between ADMA and NO synthesis was observed. The association between Si and NO production suggests a close mechanistic link between endothelial function and insulin signaling. The results may be highly informative for the development of controlled longitudinal interventions to improve endothelial and metabolic regulation.</description><dc:title>In vivo nitric oxide synthesis, insulin sensitivity, and asymmetric dimethylarginine in obese subjects without and with metabolic syndrome - Corrected Proof</dc:title><dc:creator>Mario Siervo, Les J.C. Bluck</dc:creator><dc:identifier>10.1016/j.metabol.2011.10.003</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-07</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-07</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003441/abstract?rss=yes"><title>Metabolic consequences of stress during childhood and adolescence - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003441/abstract?rss=yes</link><description>Abstract: Stress, that is, the state of threatened or perceived as threatened homeostasis, is associated with activation of the stress system, mainly comprised by the hypothalamic-pituitary-adrenal axis and the arousal/sympathetic nervous systems. The stress system normally functions in a circadian manner and interacts with other systems to regulate a variety of behavioral, endocrine, metabolic, immune, and cardiovascular functions. However, the experience of acute intense physical or emotional stress, as well as of chronic stress, may lead to the development of or may exacerbate several psychologic and somatic conditions, including anxiety disorders, depression, obesity, and the metabolic syndrome. In chronically stressed individuals, both behavioral and neuroendocrine mechanisms promote obesity and metabolic abnormalities: unhealthy lifestyles in conjunction with dysregulation of the stress system and increased secretion of cortisol, catecholamines, and interleukin-6, with concurrently elevated insulin concentrations, lead to development of central obesity, insulin resistance, and the metabolic syndrome. Fetal life, childhood, and adolescence are particularly vulnerable periods of life to the effects of intense acute or chronic stress. Similarly, these life stages are crucial for the later development of behavioral, metabolic, and immune abnormalities. Developing brain structures and functions related to stress regulation, such as the amygdala, the hippocampus, and the mesocorticolimbic system, are more vulnerable to the effects of stress compared with mature structures in adults. Moreover, chronic alterations in cortisol secretion in children may affect the timing of puberty, final stature, and body composition, as well as cause early-onset obesity, metabolic syndrome, and type 2 diabetes mellitus. The understanding of stress mechanisms leading to metabolic abnormalities in early life may lead to more effective prevention and intervention strategies of obesity-related health problems.</description><dc:title>Metabolic consequences of stress during childhood and adolescence - Corrected Proof</dc:title><dc:creator>Panagiota Pervanidou, George P. Chrousos</dc:creator><dc:identifier>10.1016/j.metabol.2011.10.005</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-07</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-07</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003453/abstract?rss=yes"><title>Maternal serum resistin at 11 to 13 weeks' gestation in normal and pathological pregnancies - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003453/abstract?rss=yes</link><description>Abstract: The objective was to examine maternal serum levels of resistin at 11 to 13 weeks' gestation in normal and pathological pregnancies. Serum resistin, pregnancy-associated plasma protein A (PAPP-A), and uterine artery pulsatility index (PI) at 11 to 13 weeks were measured in 480 singleton pregnancies, including 240 with normal outcome, 60 that subsequently developed preeclampsia (PE), 60 that developed gestational diabetes mellitus (GDM), 60 that delivered large for gestational age (LGA) neonates, and 60 that delivered small for gestational age (SGA) neonates. Each value in both the normal and pathological outcome groups was expressed as a multiple of the expected normal median (MoM), and the median MoM values in the outcome groups were compared. In the PE group, compared with the controls, there were an increase in median resistin (1.22 MoM, P = .003) and uterine artery PI (1.25 MoM, P &lt; .0001) and a decrease in serum PAPP-A (0.72, P &lt; .0001). There was no significant association between serum resistin with either uterine artery PI (P = .415) or serum PAPP-A (P = .290). In the SGA, LGA, and GDM groups, serum resistin MoM was not significantly different from that of the controls (P = .415, P = .702, and P = .549, respectively). In pregnancies that develop PE, maternal serum resistin concentration at 11 to 13 weeks is increased in a manner not related to altered placental perfusion or function. In pregnancies complicated by the development of GDM or delivery of SGA or LGA neonates, serum resistin is not significantly altered.</description><dc:title>Maternal serum resistin at 11 to 13 weeks' gestation in normal and pathological pregnancies - Corrected Proof</dc:title><dc:creator>Surabhi Nanda, Leona C.Y. Poon, Mazen Muhaisen, Isabel C. Acosta, Kypros H. Nicolaides</dc:creator><dc:identifier>10.1016/j.metabol.2011.10.006</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-07</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-07</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003465/abstract?rss=yes"><title>A tea/vanadate decoction delivered orally over 14 months to diabetic rats induces long-term glycemic stability without organ toxicity - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003465/abstract?rss=yes</link><description>Abstract: Vanadium can induce potent hypoglycemic effects in type 1 and type 2 diabetes mellitus animals, but toxic adverse effects have inhibited the translation of these findings. Administration of vanadate in a black tea decoction has shown impressive hypoglycemic effects without evidence of toxicity in short-term studies. The purpose of this study was to investigate the hypoglycemic action and the toxic adverse effects of a tea/vanadate (T/V) decoction in diabetic rats over a 14-month treatment period. Streptozotocin-induced type 1 diabetes mellitus rats were orally gavaged with 40 mg sodium vanadate in a black tea decoction only when blood glucose levels were greater than 10 mmol/L. Glycemic status and liver and kidney function were monitored over 14 months. All of the diabetic rats in this treatment group (n = 25) required treatment with the T/V decoction at the start of the study to reduce blood glucose levels to less than 10 mmol/L. Diarrhea was uncommon among the T/V-treated animals during the first week of T/V treatment and was absent thereafter. There was no evidence of liver or kidney dysfunction or injury. From 2 to 6 months, fewer animals required the T/V treatment to maintain their blood glucose levels. After 9 months of treatment, none of the diabetic animals required any T/V to maintain their blood glucose levels at less than 10 mmol/L. Oral administration of a T/V decoction provides safe, long-acting hypoglycemic effects in type 1 diabetes mellitus rats. The typical glycemic signs of diabetes were absent for the last 5 months of the study.</description><dc:title>A tea/vanadate decoction delivered orally over 14 months to diabetic rats induces long-term glycemic stability without organ toxicity - Corrected Proof</dc:title><dc:creator>Tod A. Clark, Clayton E. Heyliger, Melanie Kopilas, Andrea L. Edel, Asad Junaid, Floribeth Aguilar, Donald D. Smyth, James A. Thliveris, Michele Merchant, Hae K. Kim, Grant N. Pierce</dc:creator><dc:identifier>10.1016/j.metabol.2011.10.007</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-07</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-07</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003489/abstract?rss=yes"><title>Prediction of gestational diabetes mellitus at 24 to 28 weeks of gestation by using first-trimester insulin sensitivity indices in Asian Indian subjects - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003489/abstract?rss=yes</link><description>Abstract: The aim of the present study was to predict the development of gestational diabetes mellitus (GDM) after 24 weeks of gestation by using first-trimester insulin indices. A total of 298 nondiabetic pregnant women underwent 3-hour oral glucose tolerance test (OGTT) in the first trimester of pregnancy. The normoglycemic women underwent second OGTT between 24 and 28 weeks. Insulin sensitivity and resistance indices were calculated by using the Matsuda index (composite insulin sensitivity from OGTT), quantitative insulin sensitivity check index, and homeostasis model assessment for insulin resistance and sensitivity by using the results of the first-trimester OGTT. These indices were compared between subjects who were diagnosed as having GDM and subjects with normal glucose tolerance in the second OGTT. The overall prevalence of GDM was 15.49% (24 in the first trimester and 16 between 24 and 28 weeks). First-trimester fasting plasma insulin greater than 7.45 μU/mL was able to predict GDM with sensitivity and specificity of 80% and 57.4%, respectively. The negative predictive value for this parameter was 0.97. Values of first-trimester composite insulin sensitivity from OGTT less than 5.5 had sensitivity and specificity of 71.4% and 62.5% for the prediction of GDM. First-trimester hyperinsulinemia preceded the onset of hyperglycemia between 24 and 28 weeks of gestation and would predict the development of GDM with limited sensitivity and specificity.</description><dc:title>Prediction of gestational diabetes mellitus at 24 to 28 weeks of gestation by using first-trimester insulin sensitivity indices in Asian Indian subjects - Corrected Proof</dc:title><dc:creator>Emmy Grewal, Sandeep Kansara, Garima Kachhawa, A.C. Ammini, Alka Kriplani, Nutan Aggarwal, Nandita Gupta, Rajesh Khadgawat</dc:creator><dc:identifier>10.1016/j.metabol.2011.10.009</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-07</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-07</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003520/abstract?rss=yes"><title>Methylenetetrahydrofolate reductase C677T gene polymorphism and coronary artery disease in a Chinese Han population: a meta-analysis - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003520/abstract?rss=yes</link><description>Abstract: Methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism has been suggested to be associated with increased coronary artery disease (CAD) risk. To explore the relationship between MTHFR C677T gene polymorphism and CAD in the Chinese Han population, a meta-analysis was performed. Fourteen separate studies were included and 2981 subjects were involved in the current meta-analysis. The pooled odds ratio (OR) between CAD size to CAD size and control size (CAD/CAD + control) and the corresponding 95% confidence interval (95% CI) between the CC and TT genotype groups were estimated by a random-effects model. Meta-regression was performed to explore the heterogeneity source. The CAD/CAD + control values were 0.45 for the CC genotype group and 0.62 for the TT genotype group. The pooled OR for the CAD/CAD + control between the CC and TT genotype groups was 0.55 (95% CI, 0.37-0.83; Pheterogeneity = .0004, I2 = 64.7%). These results indicated that MTHFR C677T gene polymorphism and CAD were significantly associated (P = .005) in the Chinese Han population. Publication year was detected as the main heterogeneity source. In a stratified analysis by publication year, the pooled OR was 0.76 (95% CI, 0.37-1.57; Pheterogeneity = .0002; I2 = 79.6%) in subgroup 1 (publication years 1999-2004). No significant association between gene polymorphism and CAD was found in this subgroup (P = .46). In subgroup 2 (publication years 2005-2011), the pooled OR was 0.39 (95% CI, 0.28-0.55; Pheterogeneity = .53; I2 = 0); and the association between gene polymorphism and CAD was significant (P &lt; .00001). In the Chinese Han population, the TT genotype for the MTHFR C677T gene appeared to be associated with increased CAD risk.</description><dc:title>Methylenetetrahydrofolate reductase C677T gene polymorphism and coronary artery disease in a Chinese Han population: a meta-analysis - Corrected Proof</dc:title><dc:creator>Yan-yan Li</dc:creator><dc:identifier>10.1016/j.metabol.2011.10.013</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-07</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-07</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003544/abstract?rss=yes"><title>Effects of resistance exercise and obesity level on ghrelin and cortisol in men - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003544/abstract?rss=yes</link><description>Abstract: Resistance exercise (RE) is increasingly recommended by health organizations as a weight management tool. The purpose of this study was to examine the effects of an acute high-volume, whole-body RE protocol on the glucoregulatory and ghrelin response in sedentary obese and lean men. Five World Health Organization (WHO) class 1 obese (body mass index [BMI], 30.00-34.99) (age, 21.6 ± 2.5 years; height, 176.3 ± 3.7 cm; body mass, 97.8 ± 8.58 kg; body fat, 34.7% ± 2.95%), 5 WHO 2 (BMI, 35-39.99)/WHO 3 (BMI, ≥40) obese (age, 20.0 ± 1.4 years; height, 177.7 ± 5.15 cm; body mass, 120.8 ± 10.49 kg; body fat, 40.5% ± 5.82 %), and 9 lean men (age, 20.1 ± 2.1 years; height, 177.8 ± 8.7 cm; body mass, 71.7 ± 5.8 kg; body fat, 14.7% ± 3.54 %) completed an acute RE testing protocol (6 exercises, 3 sets of 10 repetitions at 85%-95% 10-repetition maximum with 120- and 90-second rest periods); and blood samples were collected pre-, mid-, and immediately postexercise and during recovery (+50, +70, and +110). Resistance exercise produced differences over time in cortisol, insulin, and glucose. Group differences were observed for ghrelin, with the WHO class 2/3 group having significantly greater ghrelin levels than the lean group (d = 0.28, P = .009) and the WHO class 1 group (d = 0.39, P = .002). Higher ghrelin was significantly associated with lower cortisol only in obese individuals. In addition, higher growth hormone was associated with lower ghrelin in lean individuals. Results suggest that glucoregulatory homeostasis is altered with increasing levels of obesity and that these alterations may mediate the response of cortisol and ghrelin in response to RE.</description><dc:title>Effects of resistance exercise and obesity level on ghrelin and cortisol in men - Corrected Proof</dc:title><dc:creator>Gwendolyn A. Thomas, William J. Kraemer, Brett A. Comstock, Courtenay Dunn-Lewis, Jeff S. Volek, Craig R. Denegar, Carl M. Maresh</dc:creator><dc:identifier>10.1016/j.metabol.2011.10.015</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-07</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-07</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003568/abstract?rss=yes"><title>Less fat reduction per unit weight loss in type 2 diabetic compared with nondiabetic obese individuals completing a very-low-calorie diet program - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003568/abstract?rss=yes</link><description>Abstract: The objective was to compare weight loss and change in body composition in obese subjects with and without type 2 diabetes mellitus during a very-low-calorie diet (VLCD) program. Seventy weight-matched subjects with diabetes or normal fasting glucose (controls) participated in a 24-week VLCD study. Primary end points were changes in anthropometry, body composition, and fasting plasma insulin and β-hydroxybutyrate concentrations. Fifty-one subjects (24 with diabetes) completed the study. No difference in weight loss between the 2 groups at 24 weeks was found by intention-to-treat analysis. Both groups completing the study per protocol had near-identical weight change during the program, with similar weight loss at 24 weeks (diabetes: 8.5 ± 1.3 kg vs control: 9.4 ± 1.2 kg, P = .64). Change in fat mass index correlated with change in body mass index (BMI) in both groups (diabetes: r = 0.878, control: r = 0.920, both P &lt; .001); but change in fat mass index per unit change in BMI was less in the diabetic group compared with controls (0.574 vs 0.905 decrease, P = .003), which persisted after adjusting for age, sex, and baseline BMI (P = .008). Insulin concentrations remained higher and peak β-hydroxybutyrate concentrations were lower in the diabetic compared with the control group. While following a 24-week VLCD program, obese subjects with and without diabetes achieved comparable weight loss; but the decrease in adiposity per unit weight loss was attenuated in diabetic subjects. Hyperinsulinemia may have inhibited lipolysis in the diabetic group; however, further investigation into other factors is needed.</description><dc:title>Less fat reduction per unit weight loss in type 2 diabetic compared with nondiabetic obese individuals completing a very-low-calorie diet program - Corrected Proof</dc:title><dc:creator>Scott T. Baker, George Jerums, Luke A. Prendergast, Sianna Panagiotopoulos, Boyd J. Strauss, Joseph Proietto</dc:creator><dc:identifier>10.1016/j.metabol.2011.10.017</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-07</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-07</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003416/abstract?rss=yes"><title>ENPP1 K121Q polymorphism and type 2 diabetes mellitus in the Chinese population: a meta-analysis including 11 855 subjects - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003416/abstract?rss=yes</link><description>Abstract: Ectoenzyme nucleotide pyrophosphate phosphodiesterase 1 (ENPP1) K121Q gene polymorphism has been suggested to be associated with the increased risk of developing type 2 diabetes mellitus (T2D), but relevant research results are still contradictory. To explore the relationship between ENPP1 K121Q gene polymorphism and T2D in the Chinese population, a meta-analysis was performed. Fourteen independent studies involving 11 855 subjects were retrieved from electronic databases. The pooled odds ratio (ORs) for the distribution of Q allele frequency of the ENPP1 K121Q gene and its corresponding 95% confidence interval (95% CI) were assessed using a random-effects model. Under an allelic model of inheritance, the distribution of Q allele frequency was 0.107 for the T2D group and 0.093 for the control group. The pooled OR for the distribution of Q allele frequency of ENPP1 K121Q gene was 1.29 (95% CI, 1.09-1.53; Pheterogeneity = .006; I2 = 55.6%). There was a significant association between ENPP1 K121Q gene polymorphism and T2D in the Chinese population (P = .003). Under a dominant model of inheritance, the KQ + QQ/KK value was 0.259 for the T2D group and 0.220 for the control group. The pooled OR for the KQ + QQ/KK value was 1.51 (95% CI, 1.20-1.91; Pheterogeneity &lt; .0001; I2 = 71.8%). The association between ENPP1 K121Q gene polymorphism and T2D in the Chinese population followed a dominant model of inheritance (P = .0005). In the Chinese population, the ENPP1 K121Q gene polymorphism was implied to be involved with T2D susceptibility. People with the Q allele of the ENPP1 K121Q gene might be predisposed to T2D.</description><dc:title>ENPP1 K121Q polymorphism and type 2 diabetes mellitus in the Chinese population: a meta-analysis including 11 855 subjects - Corrected Proof</dc:title><dc:creator>Yan-yan Li</dc:creator><dc:identifier>10.1016/j.metabol.2011.10.002</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-05</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-05</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003477/abstract?rss=yes"><title>Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003477/abstract?rss=yes</link><description>Abstract: Chemerin is a chemoattractant adipokine that regulates adipogenesis and may induce insulin resistance. Chemerin serum concentrations are elevated in obese, insulin-resistant, and inflammatory states in vivo. Here we investigate the role of omental (OM) and subcutaneous (SC) adipose tissue chemerin and CMKLR1 messenger RNA (mRNA) expression in human obesity. In addition, we test the hypothesis that changes in chemerin serum concentrations are primarily associated with reduced body fat mass in the context of 3 weight loss intervention studies. Chemerin serum concentration was measured in 740 individuals in a cross-sectional (n = 629) study including a subgroup (n = 161) for which OM and SC chemerin mRNA expression has been analyzed as well as in 3 interventions including 12 weeks of exercise (n = 60), 6 months of calorie-restricted diet (n = 19) studies, and 12 months after bariatric surgery (n = 32). Chemerin mRNA is significantly higher expressed in adipose tissue of patients with type 2 diabetes mellitus and correlates with circulating chemerin, body mass index (BMI), percentage body fat, C-reactive protein, homeostasis model assessment of insulin resistance, and glucose infusion rate in euglycemic-hyperinsulinemic clamps. CMKLR1 mRNA expression was not significantly different between the 2 fat depots. Obesity surgery–induced weight loss causes a significant reduction on both OM and SC chemerin expression. All interventions led to significantly reduced chemerin serum concentrations. Decreased chemerin serum concentrations significantly correlate with improved glucose infusion rate and reduced C-reactive protein levels independently of changes in BMI. Insulin resistance and inflammation are BMI-independent predictors of elevated chemerin serum concentrations. Reduced chemerin expression and serum concentration may contribute to improved insulin sensitivity and subclinical inflammation beyond significant weight loss.</description><dc:title>Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity - Corrected Proof</dc:title><dc:creator>Rima Chakaroun, Matthias Raschpichler, Nora Klöting, Andreas Oberbach, Gesine Flehmig, Matthias Kern, Michael R. Schön, Edward Shang, Tobias Lohmann, Miriam Dreßler, Mathias Fasshauer, Michael Stumvoll, Matthias Blüher</dc:creator><dc:identifier>10.1016/j.metabol.2011.10.008</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-05</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-05</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003519/abstract?rss=yes"><title>Association between serum fibroblast growth factor 21 and diabetic nephropathy - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003519/abstract?rss=yes</link><description>Abstract: Fibroblast growth factor 21 (FGF-21) is a new metabolic regulator with beneficial effects on lipid and glucose metabolism in animal models of diabetes mellitus. The aim of this study was to explore the relationship between FGF-21 and diabetic nephropathy in humans. Serum FGF-21 levels were determined in groups of control (n = 50) and type 2 diabetes mellitus (T2DM) patients with normoalbuminuria (n = 158), microalbuminuria (n = 68), and macroalbuminuria (n = 38) using enzyme-linked immunosorbent assay. Multiple linear regression models were used to analyze the associations between FGF-21 or other biomedical indices and urinary albumin excretion (UAE). Median serum FGF-21 levels were increased in T2DM patients compared with nondiabetic controls and were significantly higher in patients of higher UAE group. In groups of control and T2DM patients with normoalbuminuria, microalbuminuria, and macroalbuminuria, median serum (interquartile range) FGF-21 levels were 467.89 (294.59-519.56), 492.30 (354.59-640.42), 595.01 (480.49-792.31), and 665.20 (448.68-829.75) ng/L (P &lt; .001), respectively. After adjustment for the confounders, FGF-21, fasting plasma glucose, and high-density lipoprotein cholesterol levels were found to be independently associated with UAE in diabetic patients. Serum FGF-21 level is independently correlated with UAE in T2DM patients, indicating that circulating FGF-21 may be involved in diabetic nephropathy.</description><dc:title>Association between serum fibroblast growth factor 21 and diabetic nephropathy - Corrected Proof</dc:title><dc:creator>Wei-Xia Jian, Wen-Hui Peng, Jie Jin, Xue-Ru Chen, Wen-Jun Fang, Wei-Xing Wang, Li Qin, Yan Dong, Qing Su</dc:creator><dc:identifier>10.1016/j.metabol.2011.10.012</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-12-05</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-12-05</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003167/abstract?rss=yes"><title>Effects of hyperinsulinemia on lipoprotein lipase, angiopoietin-like protein 4, and glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 in subjects with and without type 2 diabetes mellitus - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003167/abstract?rss=yes</link><description>Abstract: Our aims were to compare the systemic effects of insulin on lipoprotein lipase (LPL) in tissues from subjects with different degrees of insulin sensitivity. The effects of insulin on LPL during a 4-hour hyperinsulinemic, euglycemic clamp were studied in skeletal muscle, adipose tissue, and postheparin plasma from young healthy subjects (YS), older subjects with type 2 diabetes mellitus (DS), and older control subjects (CS). In addition, we studied the effects of insulin on the expression of 2 recently recognized candidate genes for control of LPL activity: angiopoietin-like protein 4 (ANGPTL4) and glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1. As an effect of insulin, LPL activity decreased by 20% to 25% in postheparin plasma and increased by 20% to 30% in adipose tissue in all groups. In YS, the levels of ANGPTL4 messenger RNA in adipose tissue decreased 3-fold during the clamp. In contrast, there was no significant change in DS or CS. Regression analysis showed that the ability of insulin to reduce the expression of ANGPTL4 was positively correlated with M-values and inversely correlated with factors linked to the metabolic syndrome. Expression of glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 tended to be higher in YS than in DS or CS, but the expression was not affected by insulin in any of the groups. Our data imply that the insulin-mediated regulation of LPL is not directly linked to the control of glucose turnover by insulin or to ANGPTL4 expression in adipose tissue or plasma. Interestingly, the response of ANGPTL4 expression in adipose tissue to insulin was severely blunted in both DS and CS.</description><dc:title>Effects of hyperinsulinemia on lipoprotein lipase, angiopoietin-like protein 4, and glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 in subjects with and without type 2 diabetes mellitus - Corrected Proof</dc:title><dc:creator>Toralph Ruge, Valentina Sukonina, Olessia Kroupa, Elena Makoveichuk, Magdalena Lundgren, Maria K. Svensson, Gunilla Olivecrona, Jan W. Eriksson</dc:creator><dc:identifier>10.1016/j.metabol.2011.09.014</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-11-14</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-11-14</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003210/abstract?rss=yes"><title>Long-term recovery of β-cell function after partial pancreatectomy in humans - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003210/abstract?rss=yes</link><description>Abstract: Glucose homeostasis is significantly altered immediately after partial pancreatectomy. The present study examined the long-term consequences of a hemipancreatectomy in 10 patients with chronic pancreatitis and 10 patients with benign pancreatic and extrapancreatic tumors. A 240-minute oral glucose challenge was performed before and shortly after pancreatic surgery, as well as after a follow-up of 3.1 ± 0.5 years. Plasma concentrations of glucose, insulin, and C-peptide were determined; and indices of insulin sensitivity and insulin secretion were calculated. In both groups of patients, fasting and postchallenge glucose concentrations were significantly altered immediately after surgery, but returned to preoperative levels at the time of follow-up (P &lt; .0001). Postchallenge insulin and C-peptide concentrations were reduced immediately after surgery (P &lt; .0001), but were partly normalized at the time of follow-up (P &lt; .0001). These changes were not accompanied by improvements in insulin sensitivity (Matsuda index). However, the oral disposition index revealed a significant recovery of β-cell function at the time of follow-up (P &lt; .05). These findings demonstrate a capacity for recovery of glucose control after partial pancreatectomy and suggest that β-cell function can improve significantly over time even in adult humans.</description><dc:title>Long-term recovery of β-cell function after partial pancreatectomy in humans - Corrected Proof</dc:title><dc:creator>Bjoern A. Menge, Thomas G.K. Breuer, Peter R. Ritter, Waldemar Uhl, Wolfgang E. Schmidt, Juris J. Meier</dc:creator><dc:identifier>10.1016/j.metabol.2011.09.019</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-11-14</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-11-14</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003027/abstract?rss=yes"><title>Association between thyroid hormone levels, the number of circulating osteoprogenitor cells, and bone mineral density in euthyroid postmenopausal women - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003027/abstract?rss=yes</link><description>Abstract: In postmenopausal women, an association between reduced bone mineral density (BMD) and increased number of circulating osteoprogenitor cells (COPs) has been found. Although an increased thyroid function is associated with BMD, thyroid hormones stimulate osteoblast function in vitro. We investigated whether thyroid hormones within the reference range were correlated with the number of COPs and stimulate mineralization in vitro. The number of COPs, defined as CD34+/alkaline phosphatase (AP)+ or CD34+/osteocalcin (OCN)+ cells, was quantified by fluorescence-activated cell sorting (FACS) analysis in 150 euthyroid postmenopausal women. Participants underwent measurement of serum free thyroxine (FT4), thyroid-stimulating hormone levels, and femur BMD. CD34+ cells were isolated from healthy volunteers irrespective of AP or OCN expression, and the effect of triiodothyronine (0.5-10 pmol/L)) on their ability to form mineralized nodules in vitro was studied. The number of COPs was highest among women with high-normal FT4 levels (&gt;1.09 ng/dL). The FT4 levels were correlated positively with circulating log-CD34+/AP+ (r = 0.32, P &lt; .001) and log-CD34/OCN+ cells (r = 0.36, P &lt; .001) and inversely with total femur BMD (r = −0.17, P = .036) but not with femoral neck BMD. In a multivariate analysis, the FT4 levels were positively correlated with the number of COPs, independent of age and BMD. The ability of CD34+ cells to form mineralized nodules increased after exposure from low up to high-normal triiodothyronine concentrations (P for trend = .003). Among euthyroid postmenopausal women, high-normal FT4 levels are correlated with an increased number of circulating immature osteoprogenitor cells and a very mild BMD reduction. Exposure of CD34+ cells to physiological triiodothyronine concentrations stimulates mineralization in vitro.</description><dc:title>Association between thyroid hormone levels, the number of circulating osteoprogenitor cells, and bone mineral density in euthyroid postmenopausal women - Corrected Proof</dc:title><dc:creator>Matteo Pirro, Maria Rosaria Manfredelli, Anna Maria Scarponi, Graziana Lupattelli, Francesco Bagaglia, Francesco Melis, Elmo Mannarino</dc:creator><dc:identifier>10.1016/j.metabol.2011.09.006</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-11-11</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-11-11</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003039/abstract?rss=yes"><title>The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003039/abstract?rss=yes</link><description>Abstract: Vitamin D has been implicated in the pathophysiology of extraskeletal conditions such as hypertension, kidney disease, and diabetes via its ability to negatively regulate the renin-angiotensin system (RAS). This article reviews the evidence supporting a link between vitamin D and the RAS in these conditions, with specific emphasis on translational observations and their limitations. A literature review of animal and human studies evaluating the role of vitamin D in hypertension, kidney disease, and diabetes was performed. Excess activity of the RAS has been implicated in the pathogenesis of hypertension, chronic kidney disease, decreased insulin secretion, and insulin resistance. Animal studies provide strong support for 1,25-dihydroxyvitamin D3–mediated downregulation of renin expression and RAS activity via its interaction with the vitamin D receptor. Furthermore, the activity of vitamin D metabolites in animals is associated with reductions in blood pressure, proteinuria and renal injury, and with improved β-cell function. Many observational, and a few interventional, studies in humans have supported these findings; however, there is a lack of well-designed prospective human interventional studies to definitively assess clinical outcomes. There is a need for more well-designed prospective interventional studies to validate this hypothesis in human clinical outcomes.</description><dc:title>The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes - Corrected Proof</dc:title><dc:creator>Anand Vaidya, Jonathan S. Williams</dc:creator><dc:identifier>10.1016/j.metabol.2011.09.007</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-11-11</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-11-11</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003040/abstract?rss=yes"><title>Short-term walnut consumption increases circulating total adiponectin and apolipoprotein A concentrations, but does not affect markers of inflammation or vascular injury in obese humans with the metabolic syndrome: data from a double-blinded, randomized, placebo-controlled study - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003040/abstract?rss=yes</link><description>Abstract: Long-term consumption of walnuts is associated with lower cardiovascular disease risk in epidemiological studies, possibly through improvements in lipid profile and endothelial function. It remains to be elucidated how soon after initiation of walnut consumption beneficial effects on lipid profile and biomarkers of inflammation or vascular injury can be observed. Fifteen obese subjects (9 men and 6 women; age, 58 ± 2.5 years; body mass index, 36.6 ± 1.7 kg/m2) with the metabolic syndrome participated as inpatients in a randomized, double-blinded, placebo-controlled crossover study involving short-term placebo or walnut-enriched diet (48 g/d for 4 days). Apolipoproteins and markers of inflammation and vascular injury were measured before and after consumption of the experimental diets. Consumption of walnuts was associated with a statistically significant increase in serum apolipoprotein A concentrations (P = .03), but did not affect circulating levels of fetuin A, resistin, C-reactive protein, serum amyloid A, soluble intercellular adhesion molecules 1 and 3, soluble vascular cell adhesion protein 1, interleukins 6 and 8, tumor necrosis factor α, E-selectin, P-selectin, and thrombomodulin. Four days of walnut consumption (48 g/d) leads to mild increases in apolipoprotein A concentrations, changes that may precede and lead to the beneficial effects of walnuts on lipid profile in obese subjects with the metabolic syndrome.</description><dc:title>Short-term walnut consumption increases circulating total adiponectin and apolipoprotein A concentrations, but does not affect markers of inflammation or vascular injury in obese humans with the metabolic syndrome: data from a double-blinded, randomized, placebo-controlled study - Corrected Proof</dc:title><dc:creator>Konstantinos N. Aronis, Maria T. Vamvini, John P. Chamberland, Laura L. Sweeney, Aoife M. Brennan, Faidon Magkos, Christos S. Mantzoros</dc:creator><dc:identifier>10.1016/j.metabol.2011.09.008</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-11-11</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-11-11</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003052/abstract?rss=yes"><title>The association between triglyceride to high-density-lipoprotein cholesterol ratio and insulin resistance in a multiethnic primary prevention cohort - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003052/abstract?rss=yes</link><description>Abstract: The objective was to explore the clinical utility of triglyceride (TG) to high-density lipoprotein cholesterol (HDL-C) ratio in predicting insulin resistance (IR) in 4 ethnic groups and the relationship between IR and TG/HDL-C in comparison to that with other lipid measures. Apparently healthy Aboriginals, Chinese, Europeans, and South Asians (N = 784) were assessed for sociodemographics, lifestyle, anthropometry, lipids, glucose, and insulin. The homeostasis model assessment of IR was used as a measure of IR. Compared with other lipid parameters, TG/HDL-C was the highest correlate of the homeostasis model assessment of IR (age and sex adjusted) in Aboriginals (r = 0.499, P &lt; .001), Chinese (r = 0.432, P &lt; .001), Europeans (r = 0.597, P &lt; .001), and South Asians (0.372, P &lt; .001). For a 1-unit increase in TG/HDL-C, the odds of being insulin resistant increased about 4 times (odds ratio [OR], 3.95; 95% confidence interval [CI], 1.86-8.42; P &lt; .001) in Aboriginals, 3.4 times in Chinese (OR, 3.44; 95% CI, 1.79-6.62; P &lt; .001), 1.9 times in Europeans (OR, 1.94; 95% CI, 1.00-3.75; P = .049), and 1.8 times in South Asians (OR, 1.77; 95% CI, 0.91-3.45; P = .094) (age, sex, smoking, physical activity, body mass index, and waist circumference adjusted). Receiver operating characteristic curve analyses revealed areas under the curve (95% CI) of 0.777 (0.707-0.847) in Aboriginals, 0.723 (0.647-0.798) in Chinese, 0.752 (0.675-0.828) in Europeans, and 0.676 (0.590-0.762) in South Asians. Optimal cutoffs (sensitivity, specificity) of TG/HDL-C for identifying individuals with IR were 0.9 (93.0%, 51.9%), 1.1 (71.7%, 61.5%), 1.1 (73.5%, 70.9%), and 1.8 (52.0%, 77.9%) in Aboriginal, Chinese, European, and South Asian individuals, respectively. The TG/HDL-C ratio may be a good marker to identify insulin-resistant individuals of Aboriginal, Chinese, and European, but not South Asian, origin.</description><dc:title>The association between triglyceride to high-density-lipoprotein cholesterol ratio and insulin resistance in a multiethnic primary prevention cohort - Corrected Proof</dc:title><dc:creator>Danijela Gasevic, Jiri Frohlich, G.B. John Mancini, Scott A. Lear</dc:creator><dc:identifier>10.1016/j.metabol.2011.09.009</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-11-11</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-11-11</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003143/abstract?rss=yes"><title>Decreased insulin secretion in islets from protein malnourished rats is associated with impaired glutamate dehydrogenase function: effect of leucine supplementation - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003143/abstract?rss=yes</link><description>Abstract: We herein studied the role of glutamate dehydrogenase (GDH), in response to leucine (LEU) supplementation, upon insulin secretion of malnourished rats. Weaned male Wistar rats were fed normal-protein (17%) or low-protein diet (6%, LP) for 8 weeks. Half of the rats of each group were supplemented with LEU (1.5%) in the drinking water for the following 4 weeks. Gene and protein expressions, static insulin secretion, and cytoplasmic Ca2+ oscillations were measured. Glutamate dehydrogenase messenger RNA was 58% lower in LP islets, and LEU supplementation augmented it in 28%. The LP islets secreted less insulin when exposed to 20 mmol/L LEU, 20 mmol/L LEU + 2 mmol/L glutamine (with or without 5 mmol/L aminooxyacetic acid, a branched chain aminotransferase inhibitor, or 20 μmol/L epigallocatechin gallate, a GDH inhibitor), 20 mmol/L α-ketoisocaproate, glutamine + 20 mmol/L β-2-aminobicyclo[2.2.1]heptane-2-carboxylic acid (a GDH activator), and 22.2 mmol/L glucose. Leucine supplementation augmented insulin secretion to levels found in normal-protein islets in all the above conditions, an effect that was blunted when islets were incubated with epigallocatechin gallate. The glutamine + β-2-aminobicyclo[2.2.1]heptane-2-carboxylic acid–induced increased [Ca2+]i and oscillations were higher than those for LP islets. Leucine supplementation normalized these parameters in LP islets. Impaired GDH function was associated with lower insulin release in LP islets, and LEU supplementation normalized insulin secretion via restoration of GDH function. In addition, GDH may contribute to insulin secretion through ameliorations of Ca2+ handling in LP islets.</description><dc:title>Decreased insulin secretion in islets from protein malnourished rats is associated with impaired glutamate dehydrogenase function: effect of leucine supplementation - Corrected Proof</dc:title><dc:creator>Priscilla Muniz Ribeiro da Silva, Thiago Martins Batista, Rosane Aparecida Ribeiro, Claudio Cesar Zoppi, Antonio Carlos Boschero, Everardo Magalhães Carneiro</dc:creator><dc:identifier>10.1016/j.metabol.2011.09.012</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-11-11</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-11-11</prism:publicationDate></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003179/abstract?rss=yes"><title>Resveratrol: is selectivity opening the key to therapeutic effects? - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003179/abstract?rss=yes</link><description>The rapid increase in obesity-related diseases such as diabetes, cardiovascular disease, and cancer is becoming a significant biomedical and socioeconomic burden. Defining the biological and pathophysiological basis of these metabolic disorders as well as novel appropriate therapies is a priority for current research. Better therapeutic agents are needed to help ameliorate the current epidemic. Resveratrol, a natural plant-derived polyphenolic compound that is abundant in berries, grapes, wines, and peanuts, and its synthetic activators are among the promising new therapeutic agents that have been proposed and are currently being researched as a potential treatment of metabolic diseases such as obesity and type 2 diabetes mellitus .</description><dc:title>Resveratrol: is selectivity opening the key to therapeutic effects? - Corrected Proof</dc:title><dc:creator>Seung-Hwan Lee, Christos Mantzoros, Young-Bum Kim</dc:creator><dc:identifier>10.1016/j.metabol.2011.09.015</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-11-11</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-11-11</prism:publicationDate><prism:section>EDITORIAL</prism:section></item><item rdf:about="http://www.metabolismjournal.com/article/PIIS0026049511003180/abstract?rss=yes"><title>In mammalian muscle, SIRT3 is present in mitochondria and not in the nucleus; and SIRT3 is upregulated by chronic muscle contraction in an adenosine monophosphate-activated protein kinase–independent manner - Corrected Proof</title><link>http://www.metabolismjournal.com/article/PIIS0026049511003180/abstract?rss=yes</link><description>Abstract: In selected cell lines, it appears (a) that metabolic stressors induce the translocation of SIRT3 from the nucleus to mitochondria and (b) that SIRT3 may contribute to the regulation of mitochondrial biogenesis and/or fatty acid utilization. We have examined in mammalian muscle (1) the association between SIRT3 protein content and muscle oxidative capacity and mitochondrial fatty acid oxidation, (2) the subcellular location of SIRT3, (3) whether exercise induces the translocation of SIRT3 from the nucleus to the mitochondria, and (4) the response of SIRT3 protein to stressors known to induce mitochondrial biogenesis (chronic muscle stimulation and 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside administration). SIRT3 protein displayed hierarchical expression based on oxidative potential of muscle tissues (heart &gt;&gt; red &gt;&gt; white). In contrast to studies in some cell lines, metabolic stress (exercise) did not induce the translocation of SIRT3 from the nucleus to mitochondria, as SIRT3 was only present in subsarcolemmal (SS) and intermyofibrillar (IMF) mitochondria, not in the nucleus. Chronic stimulation increased muscle mitochondrial content and SIRT3 protein in SS (+33%) and IMF (+27%) mitochondria (P &lt; .05). In contrast, chronic 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside administration, while inducing mitochondrial biogenesis, did not alter SS or IMF mitochondrial SIRT3 protein content. These studies have shown that, in muscle, SIRT3 (a) scales with muscle oxidative capacity and with enzymes regulating fatty acid oxidation, (b) in resting muscle is localized to SS and IMF mitochondria and not nuclei, (c) in contracting muscle is not acutely translocated to mitochondria, and (d) is upregulated with chronic stimulation in an adenosine monophosphate–activated protein kinase–independent manner.</description><dc:title>In mammalian muscle, SIRT3 is present in mitochondria and not in the nucleus; and SIRT3 is upregulated by chronic muscle contraction in an adenosine monophosphate-activated protein kinase–independent manner - Corrected Proof</dc:title><dc:creator>Brendon J. Gurd, Graham P. Holloway, Yuko Yoshida, Arend Bonen</dc:creator><dc:identifier>10.1016/j.metabol.2011.09.016</dc:identifier><dc:source>Metabolism - Clinical and Experimental (2011)</dc:source><dc:date>2011-11-11</dc:date><prism:publicationName>Metabolism - Clinical and Experimental</prism:publicationName><prism:publicationDate>2011-11-11</prism:publicationDate></item></rdf:RDF>
